| 5-alpha-Reductase deficiency | 2426 |
| 5-Fluorouracil/oxaliplatin combined therapy | 2030 |
| 6-Mercaptopurine sensitivity | 1049 |
| 11β-Hydroxysteroid dehydrogenase type 2 deficiency | 1124 |
| 22q13.2 deletion syndrome | 1438 |
| 46,XX/SRY-negative true hermaphrodite | 1946 |
| 46,XY Disordered sex development and androgenization at adrenarche | 1947 |
| A | |
| ABCA1 and ACAT2 mutant phenotypes | 815 |
| ABCG2 demethylation | 1000 |
| ABCG2 inhibitors | 1000 |
| ABCG2-ABCB1 synergism | 1000 |
| Abdominal and urinary tract infections | 341 |
| Abdominal aortic aneurysm | 1125, 1224, 1947, 2152, 2277, 2297, 2336 |
| Abdominal surgery | 263 |
| Abetalipoproteinemia | 1119, 2292 |
| Abnormal uterine bleeding | 456, 535, 621 |
| Abscess | 255 |
| Absence (petit mal) seizures | 286 |
| Acatalasia | 1213 |
| Acceleration of transit of barium through small bowel | 687 |
| Acetaldehyde-derived DNA adducts | 1593 |
| Acetaminophen toxicity | 9 |
| Achlorhydria | 78 |
| Acid indigestion | 160, 296 |
| Acidosis | 691 |
| Acne | 248, 255, 412, 672, 731 |
| Acne rosacea | 74 |
| Acne vulgaris | 61, 74, 276, 707, 718, 2197 |
| Acquired idiopathic sideroblastic anemia (AISA) | 2281 |
| Acquired immunodeficiency syndrome | 769, 770, 780, 2212, 2215 |
| Acromegaly | 94, 415, 539, 572, 2088, 2428 |
| ACTH-dependent Cushing’s syndrome | 185 |
| ACTH-independent macronodular adrenal hyperplasia | 2090 |
| Actinic keratosis | 31, 223, 379 |
| Activated polyamine catabolism | 1913 |
| Activating mutations in the GNAS gene | 2090 |
| Activating transcription factor-4 | 1594 |
| Active benign ulcer | 645 |
| Activins and Inhibins | 1947 |
| Acute agitation | 805 |
| Acute and chronic respiratory tract infections | 700 |
| Acute asthma | 673, 804, 1075, 1267 |
| Acute bacterial otitis media | 129, 137 |
| Acute bacterial sinusitis | 63, 426 |
| Acute bronchitis | 745 |
| Acute bronchospasm | 673, 745 |
| Acute cardiac ischemic events | 3 |
| Acute coronary syndrome | 176, 739, 746, 1035, 1268, 1407, 2016, 2206, 2368 |
| Acute eosinophilic leukemia (AEL) | 1046 |
| Acute exacerbation of chronic bronchitis | 128, 129, 130, 162, 435, 503, 664, 731, 768 |
| Acute exacerbation of multiple sclerosis | 186 |
| Acute gout | 5, 724 |
| Acute gouty arthritis | 291, 617, 709, 764 |
| Acute graft vs host disease | 2215, 2444 |
| Acute heart failure | 227, 636, 637, 1071 |
| Acute hepatic porphyria | 1100 |
| Acute herpes zoster | 779, 810 |
| Acute hypoxia | 556, 1643 |
| Acute intermittent porphyria | 152, 356 |
| Acute intestinal amebiasis | 743 |
| Acute iritis | 773 |
| Acute iron intoxication | 206 |
| Acute ischemic events | 87 |
| Acute ischemic stroke | 25, 611, 1079 |
| Acute leukemia | 373, 836, 1594 |
| Acute lymphoblastic leukemia (ALL) | 465, 836, 932, 966, 1025, 1280, 1643, 2063, 2084, 2108, 2137, 2182, 2248, 2255, 2286, 2297, 2316, 2368, 2405, 2477, 2480, 2527 |
| Acute lymphocytic (lymphoblastic) leukemia | 190 |
| Acute lymphocytic leukemia | 52, 195, 569, 723, 792 |
| Acute manic episodes | 49, 635, 805 |
| Acute maxillary sinusitis | 129 |
| Acute mountain sickness | 8, 2299 |
| Acute myeloblastic leukemia | 1439, 2435 |
| Acute myelocytic leukemia | 190 |
| Acute myelogenous (nonlymphocytic) leukemia | 734 |
| Acute myelogenous leukemia | 340, 675, 795, 1046, 2331 |
| Acute myeloid leukemia | 195, 305, 373, 836, 966, 1000, 1440, 1643, 1987, 2021, 2063, 2119, 2237, 2279, 2393 |
| Acute myocardial failure | 643 |
| Acute myocardial infarction | 25, 482, 611, 626, 651, 703, 1072, 1250, 2518 |
| Acute organ rejection | 197 |
| Acute otitis media | 63, 134, 167, 709, 768, 769 |
| Acute pain | 139, 409, 502, 717 |
| Acute painful musculoskeletal conditions | 189 |
| Acute painful shoulder | 709 |
| Acute pancreatitis | 624, 2368 |
| Acute promyelocytic leukemia | 50, 763 |
| Acute psychotic episodes | 49 |
| Acute pulmonary edema | 333 |
| Acute pulmonary embolism | 25, 744, 777, 797 |
| Acute pyelonephritis | 426 |
| Acute rejection of renal transplant | 504 |
| Acute renal allograft rejection | 45, 504, 505 |
| Acute renal failure | 450 |
| Acute respiratory depression | 107 |
| Acute respiratory syndrome | 2055 |
| Acute rhinitis | 556 |
| Acute sinusitis | 162 |
| Acute temporomandibular joint pain | 472 |
| Acute tenosynovitis | 764 |
| Acute upper gastrointestinal bleeding | 1381 |
| Acute/subacute bursitis | 764 |
| Acute-phase reaction | 812 |
| ADA deficiency | 1048 |
| Addictive disorders | 1351 |
| Addictive behavior | 1989 |
| Adenocarcinoma | 308, 1113, 1280, 2027, 2375 |
| Adenocarcinoma of breast or ovary | 736 |
| Adenocarcinoma of stomach or pancreas | 494 |
| Adenoid cystic carcinoma | 2238 |
| Adenoma or hyperplastic polyp risk | 2366 |
| Adenomatous polyposis coli | 1113 |
| Adenosine deaminase deficiency | 569 |
| Adenoviral vectors | 1644 |
| Adiponectin | 815, 1060 |
| Adiposity | 2036, 2206 |
| Adjunct anesthetic in ophthalmic surgery | 624 |
| Adolescent idiopathic scoliosis | 2206, 2290 |
| Adrenal adenomas | 1934 |
| Adrenal steroidogenesis | 1934 |
| Adrenocortical carcinoma | 495 |
| Adrenocortical insufficiency | 186, 187, 312, 363, 764 |
| Adrenogenital syndrome | 312 |
| Adriamycin-induced glomerulosclerosis | 1125 |
| Adult-onset hypogonadotropic hypogonadism | 1947 |
| Advanced macular degeneration | 2250 |
| Adverse drug effects | 2491 |
| AEBP1 (Adipocyte enhancer-binding protein 1) | 1125 |
| Aerodigestive tract cancer | 1594 |
| Aflatoxin-related hepatocarcinogenesis | 2108 |
| African trypanosomiasis | 712 |
| Age- and sex-related effects | 1481 |
| AGER/NOTCH4 | 1126 |
| Age-related changes | 836, 988, 1001, 1359, 1440, 1594, 1645, 1913, 1947 |
| Age-related differences | 1381 |
| Age-related eye disorders | 2102 |
| Age-related hearing impairment | 2119 |
| Age-related macular degeneration | 1125, 1245, 2133, 2136, 2143, 2452 |
| Age-related macular degeneration type 5 | 2033 |
| Age-related macular dystrophy | 2450 |
| Aggression-related traits | 988 |
| Aggressive behavior | 1947, 2160 |
| Aggressive fibromatosis | 2238 |
| Aging | 932, 1126, 1487, 1489 |
| Agitated states | 810 |
| Agitation | 37 |
| Agranulocytosis | 1457 |
| AICA-ribosiduria | 1191 |
| AIDS | 967, 2126, 2130, 2133, 2136, 2206, 2182 |
| AIDS-related Kaposi’s sarcoma | 387, 559, 791 |
| Airway diseases | 673 |
| Airway obstruction | 381, 726, 732 |
| Albright hereditary osteodystrophy | 2090 |
| Alcohol (Ethyl) biodisposition | 1056 |
| Alcohol abstinence | 4 |
| Alcohol abuse | 1054, 2079 |
| Alcohol consumption | 2305 |
| Alcohol dependence | 1052, 1054, 1055, 1104, 1250, 1255, 1266, 1997, 2160, 2419 |
| Alcohol dependence, susceptibility to | 1250, 1255, 1997, 2079 |
| Alcohol metabolism and alcoholism | 1055, 1101, 1467 |
| Alcohol use disorders | 147, 1595 |
| Alcohol-associated cancer | 1055 |
| Alcoholic cardiomyopathy | 1595 |
| Alcoholic fatty liver | 2343 |
| Alcoholic liver cirrhosis | 1595 |
| Alcoholic liver disease | 1054, 1105, 1467, 2215 |
| Alcoholic steatohepatitis | 1595 |
| Alcohol-induced liver injury | 1595 |
| Alcoholism | 166, 733, 1054, 1055, 1065, 1101, 1105, 1647, 1999, 2322, 2394, 2398 |
| Alcoholism, susceptibility to | 1065, 1999 |
| Alcohol-related breast cancer | 1056 |
| Alcohol-related cancer | 1054 |
| Alcohol-related colorectal cancer | 1056 |
| Alcohol-related pathology | 1105 |
| Aldosterone synthase (CYP11B2) | 1935 |
| Aldosterone synthase (CYP11B2) inhibitors | 1935 |
| Aldosterone synthase deficiency type I | 1935 |
| Aldosterone-producing adenomas | 1934 |
| Alert classifications in product labeling | 1647 |
| Allergic asthma | 544, 673, 804 |
| Allergic conditions | 622 |
| Allergic conjunctivitis | 62, 75, 266, 771 |
| Allergic dermatosis | 232, 610, 613 |
| Allergic disorders | 187, 613 |
| Allergic rhinitis | 54, 62, 95, 211, 232, 254, 322, 425, 499, 551, 764, 771, 1648, 2438 |
| Allergic skin manifestations | 771 |
| Allergic states | 613, 764 |
| Allergy | 214, 232, 613 |
| Allogenic bone marrow transplantation | 675 |
| Alloimmune thrombocytopenia | 2226 |
| Alloimmunity | 837 |
| Alopecia areata | 764 |
| Alpers’ syndrome | 2334 |
| Alpers-Huttenlocher syndrome |
2334 |
| alpha-1-Antitrypsin deficiency | 23 |
| Altitude illness | 1935 |
| Alveolar echinococcosis | 1650 |
| Alzheimer’s disease 1, APP-related | 1165 |
| Alzheimer’s disease, susceptibility to | 812, 1195, 1220, 1249, 1263, 2071 |
| Alzheimer’s disease | 166, 240, 272, 335, 360, 460, 713, 750, 805, 812, 816, 837, 988, 991, 1001, 1029, 1094, 1109, 1115, 1126, 1165, 1195, 1202, 1211, 1213, 1220, 1224, 1230, 1249, 1258, 1263, 1441, 1948, 1980, 2036, 2071, 2100, 2112, 2113, 2127, 2130, 2146, 2158, 2169, 2192, 2206, 2211, 2215, 2242, 2258, 2263, 2281, 2299, 2303, 2307, 2319, 2332, 2336, 2349, 2358, 2369, 2419, 2422, 2444, 2455, 2470, 2518 |
| Ambient particulate matter | 1280 |
| Amblyopia | 166 |
| Amebiasis | 229 |
| Amebic liver abscess | 743 |
| Amebic meningoencephalitis | 39 |
| Amenorrhea | 535, 2036 |
| Aminoglycoside-induced and nonsyndromic hearing loss | 2281, 2282 |
| Aminoglycoside-induced deafness | 2284 |
| AMME complex | 1044 |
| Amnestic dementia | 1128 |
| Amyloid A3 | 1948 |
| Amyloid polyneuropathy-nephropathy Iowa type | 1116 |
| Amyotrophic lateral sclerosis | 656, 839, 1111, 1129, 2360 |
| Anaerobic bacterial and protozoal infections | 483 |
| Anaerobic infections | 377 |
| Analgesic response | 2267 |
| Anaphylactic reactions | 266, 622 |
| Androgen deficiency | 728 |
| Androgen insensitivity syndrome | 1184 |
| Androgenetic alopecia | 492 |
| Anemia | 202, 268, 269, 366, 511, 556, 2227 |
| Aneurysm | 1129 |
| Angina | 355, 399, 525, 742, 2060 |
| Angina pectoris | 41, 56, 227, 399, 403, 482, 507, 533, 626, 742, 788, 2060 |
| Angioedema | 121, 184, 771 |
| Angiofibroma | 2268 |
| Angiogenesis | 1129, 1615 |
| Angiotensin-converting enzyme inhibitor (ACEi)-induced cough | 2361 |
| Angle-closure glaucoma | 222, 256, 590 |
| Anhaptoglobinemia | 2152 |
| Ankylosing spondylitis | 5, 11, 139, 223, 284, 291, 348, 383, 384, 512, 709, 724, 1273, 1444, 2133, 2136, 2192, 2429, 2465 |
| Anogenital pruritus | 78, 212, 226, 253, 610 |
| Anorectal surgical wounds | 798 |
| Anorexia | 249, 458, 2036, 2161, 2398, 2476 |
| Antagonistic pleiotropy | 1129 |
| Anterior cruciate ligament (ACL) ruptures | 1261 |
| Anterior uveitis | 657 |
| Anthropometric parameters | 1949 |
| Antibiotic-associated pseudomembranous colitis produced by Clostridiuim difficile | 783 |
| Antibody-induced pure red cell aplasia | 190 |
| Anticholinesterase inhibitor poisoning | 59 |
| Anticonvulsant hypersensitivity syndrome | 2021 |
| Antidepressant exposure in breastfed infants | 1557 |
| Antidepressants in late pregnancy | 1555 |
| Antihypertensive therapy | 2023, 2304 |
| Anti-inflammatory phenotype | 1130 |
| Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) | 1273 |
| Antiphospholipid syndrome | 1381, 2056 |
| Antipsychotic-induced extrapyramidal side-effects | 1523 |
| Antipsychotic-induced obesity | 2005, 2165 |
| Antipsychotic-induced parkisonism | 2380 |
| Antipsychotic-induced side-effects | 1063 |
| Antipsychotic-induced tardive dyskinesia | 2002, 2004, 2289 |
| Antiretroviral therapy | 1224 |
| Antiretroviral therapy-associated lipid disorders | 1130 |
| Antisocial behavior | 2259 |
| Antithrombotic therapy | 1407 |
| Anti-tuberculosis drug-induced hepatic injury | 2496 |
| Anti-tuberculosis drug-induced hepatitis | 1407 |
| Anti-tuberculosis drug-induced maculopapular eruption | 1381 |
| Antitumor prodrug development | 1658 |
| Anti-VEGF therapy | 1130 |
| Antley-Bixler craniosynostosis syndrome (cytochrome P450 oxidoreductase deficiency) | 1949, 1957 |
| Anthracycline-induced extravasation | 217 |
| Anuria | 450 |
| Anxiety disorder | 23, 35, 37, 93, 102, 103, 144, 147, 177, 220, 245, 251, 368, 439, 450, 464, 552, 620, 702, 1061, 2079, 2476 |
| Anxious depression | 450, 2305 |
| Aortic aneurysm | 2290 |
| Aortic coarctation | 1935 |
| Aphthous ulcers | 119, 449 |
| Aplastic anemia | 45, 1659, 2182, 2441, 2444 |
| Apnea | 244, 1130, 1195 |
| Apnea of prematurity | 107, 732 |
| ApoA-I mimetic peptide 4F | 1130 |
| ApoB-100 | 1130 |
| APOE and lipid metabolism | 1128 |
| APOE haplotype | 1131 |
| APOE in Alzheimer’s disease | 1126, 1128 |
| ApoE receptor 2 | 1131 |
| ApoE-/- PGC-1α-/- mice | 1131 |
| ApoE-1 mimetic peptide D4-F | 816 |
| APOE-related phenotypic profiles in Alzheimer’s disease | 1128 |
| Apolipoprotein B peptide vaccine | 1131 |
| Apolipoprotein E 72-166 peptides | 1131 |
| Apoptosis | 989 |
| Apoptosis signal-regulating kinase 1 | 1131 |
| APP and presenilins in Alzheimer’s disease | 1166 |
| APP-related cerebral amyloid angiopathy | 1169 |
| Argininemia | 1189 |
| Ariboflavinosis | 653 |
| Aromatase (CYP19A1) | 1949 |
| Aromatase and dual aromatase-steroid sulfatase inhibitors | 1950 |
| Aromatase deficiency | 1949 |
| Aromatase excess syndrome | 1949 |
| Aromatase inhibitor-induced arthralgia in breast cancer | 1950 |
| Aromatase inhibitors vs Tamoxifen in advanced breast cancer | 1951 |
| Aromatic L-amino acid decarboxylase deficiency (AADC) | 1448, 1989 |
| Arrhythmia | 565, 2389 |
| Arsenic metabolism | 1190 |
| Arsenic poisoning | 2112, 2113 |
| Arsenic toxicity | 2119 |
| Arsenic-induced disease | 1190, 1220 |
| Arterial hypertension | 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 1063, 1068, 1071, 1077, 1081, 1197, 1202, 2014 |
| Arterial properties | 1051 |
| Arteriosclerosis | 182, 1914, 2521 |
| Arteriosclerosis obliterans | 401 |
| Arteriovenous fistula stenosis | 2277 |
| Arthralgia | 234 |
| Arthritis | 144, 155, 284, 455, 673, 772 |
| Arthrosis | 724 |
| Aryl hydrocarbon receptor | 841, 1002, 1132, 1280, 1337 |
| Aryl hydrocarbon receptor-interacting protein (AIP) | 1306 |
| ASA-intolerant myocardial infarct | 2439 |
| Asbestosis | 2114 |
| Ascites | 15, 285 |
| Aseptic prophylaxis of burns | 685 |
| Aspergillosis | 402 |
| Aspergillus infection | 39, 126, 2452 |
| Aspirin hypersensitivity | 2202 |
| Aspirin intolerance | 1382 |
| Aspirin-induced asthma | 2311, 2439 |
| Aspirin-induced peptic ulcer | 1381, 2439 |
| Aspirin-intolerant asthma (AIA) | 2360, 2361, 2362, 2363, 2366 |
| Assisted Reproductive Technology | 621, 777 |
| Association of APOE with beta-amyloid and tau proteins in AD pathology | 1127 |
| Association of APOE-4 with an anticipation of the age-at-onset and fast cognitive decline | 1127 |
| Association of CYP2D6 variants with Alzheimer’s disease-related genes | 1442 |
| Asthma | 69, 97, 187, 211, 253, 322, 328, 467, 499, 500, 673, 801, 804, 933, 1044, 1048, 1050, 1075, 1109, 1116, 1214, 1225, 1267, 1271, 1273, 1337, 1408, 1615, 1980, 2055, 2105, 2112, 2115, 2182, 2202, 2219, 2224, 2256, 2349, 2361, 2369, 2417, 2437, 2439, 2444, 2452, 2514 |
| Asthma, susceptibility to | 1075 |
| Astrocyte elevated gene-1 (AEG1) | 841 |
| Astrocytes | 1132 |
| Astrocytic and oligodendroglial brain tumors | 1002 |
| Astrocytoma | 124, 721, 1002, 2115 |
| Asystole | 59, 266, 785 |
| Ath29 | 1132 |
| Atherosclerosis | 57, 323, 611, 667, 816, 989, 1089, 1109, 1116, 1132, 1225, 1244, 1269, 1663, 1935, 1980, 2056, 2060, 2092, 2222, 2248, 2325, 2327, 2339, 2341, 2343, 2362, 2384, 2444, 2465 |
| Atherosclerosis, susceptibility to | 1269, 2092 |
| Athlete’s foot | 681, 692, 707, 725, 753, 763, 776 |
| Atopic dermatitis | 42, 78, 314, 322, 590, 714, 2202, 2219 |
| ATP-binding cassette transporter G1 deficiency | 989 |
| Atrial fibrillation | 6, 238, 250, 279, 372, 618, 623, 626, 637, 699, 788, 789, 797, 1030, 1085, 1935, 2304 |
| Atrial flutter | 250, 279, 372, 618, 626, 699, 788 |
| Atrioventricular nodal block | 265 |
| Attention-deficit hyperactivity disorder (ADHD) | 38, 56, 216, 218, 255, 432, 470, 478, 787, 1063, 1065, 1068, 1351, 1997, 2005, 2007, 2090, 2160, 2161, 2162, 2259, 2260, 2394, 2396, 2398, 2418, 2476 |
| Attention-deficit hyperactivity disorder, susceptibility to | 1063, 1065, 1068, 1997, 2005, 2007, 2090 |
| Atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung | 1951 |
| Atypical depression | 2259 |
| Autism | 1048, 1061, 1951, 2095, 2108, 2162, 2166, 2226, 2258, 2270, 2289, 2318 |
| Autism spectrum disorder | 658, 1061, 2095, 2289, 2318 |
| Autistic disorder | 658, 2318 |
| Autoimmune Addison’s disease | 1273 |
| Autoimmune disorders | 1273, 2401 |
| Autoimmune hemolytic anemia | 190 |
| Autoimmune hepatitis | 1449, 1540, 2143 |
| Autoimmune hypothyroidism | 2203 |
| Autologous hCD40L/IL-2 tumor vaccine | 1002 |
| Autonomic nervous system dysfunction | 2005 |
| Autosomal dominant dopa-responsive dystonia | 2081 |
| Autosomal dominant periodic fever syndrome | 2465 |
| Autosomal dominant retinitis pigmentosa | 2223 |
| Autosomal dominant thrombophilia | 2353 |
| Autosomal dominant type III hyperlipoproteinemia | 1132 |
| Autosomal recessive dopa-responsive dystonia with or without hyperphenylalaninemia | 2081 |
| Autosomal recessive juvenile Parkinson’s disease 2 | 2326 |
| Autosomal recessive mental retardation 6 | 2095 |
| Autosomal recessive spastic paraplegia 7 | 2425 |
| Autosomal recessive thrombophilia | 2353 |
| AV nodal block | 59, 398 |
| AV nodal re-entrant tachycardias | 626 |
| AWP1 Protein characterization | 2529 |
| Axenfeld-Rieger syndrome | 1337 |
| Axillary node tumor | 267 |
| Azoospermia, oligospermia | 1233, 1665, 2119 |
| B | |
| B-cell chronic lymphocytic leukemia | 18, 380 |
| Babesia microti infection | 638 |
| Bacillus Calmette-Guérin and Salmonella infection | 2219 |
| Bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder | 781 |
| Bacterial conjunctivitis | 63, 426, 503, 613, 707 |
| Bacterial Eikenella corrodens infections | 133 |
| Bacterial infections | 39, 137, 178, 208, 255, 276, 341, 380, 430, 483, 492, 558, 575, 576, 594, 598, 769 |
| Bacterial infections of the eye | 316 |
| Bacterial meningitis | 465 |
| Bacterial sepsis | 2466 |
| Bacterial septicemia | 137, 377 |
| Bacterial sinusitis | 503 |
| Bacterial vaginosis | 169, 412, 483, 743 |
| Baldness | 1185 |
| Balkan endemic nephropathy | 1666 |
| Bariatric surgery | 990 |
| Bariatric surgery-induced weight loss | 1596 |
| Barrett’s metaplasia | 1666 |
| Bartter- and Gitelman-like syndromes | 1936 |
| Basal cell carcinoma | 316, 379 |
| Basal cell nevus syndrome | 1281, 1450, 2109 |
| B-cell lymphoma | 843 |
| Beckwith-Wiedemann syndrome | 2190 |
| Bee stings | 73, 255 |
| Behavioral symptoms | 1133 |
| Behcet’s disease | 732, 1274, 2176, 2206, 2212, 2224, 2401, 2455 |
| Beneficial body composition | 2316 |
| Benign essential blepharospasm |
2007 |
| Benign facial lentigines | 718 |
| Benign familial tremor | 617 |
| Benign gastric ulcer | 296, 415, 534, 545, 645 |
| Benign metastasizing leiomyoma | 1951 |
| Benign prostate hyperplasia | 19, 252, 612, 685, 716, 725, 1063, 1098, 1666, 1951 |
| Benzene toxicity | 1596, 2021, 2109, 2307 |
| Benzodiazepine intoxication | 312 |
| Benzodiazepine-induced sedation | 312 |
| Berardinelli-Seip congenital generalized lipodystrophy (type 1) | 1083 |
| Beryllium disease | 2138 |
| beta-Amyloid | 817 |
| beta-Hemolytic streptococci | 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 140, 178, 540, 549 |
| beta-Thalassemia | 977, 2125 |
| Bilateral adrenal incidentalomas | 2316 |
| Bilateral striatal necrosis | 2280, 2283 |
| Bile acid homeostasis | 1914 |
| Bile acid metabolism | 1668 |
| Bile acid-activated vitamin D receptor signaling | 1914 |
| Bile salt deficiency | 456 |
| Biliary and renal colic | 368 |
| Biliary atresia | 2518 |
| Biliary cholesterol excretion | 844 |
| Biliary epithelium | 1669 |
| Biliary tract cancer | 1408 |
| Biliary tract infections | 129 |
| BIN1 | 1133 |
| Bioartificial liver systems | 1669 |
| Biotin deficiency | 84 |
| Biotransformation of antidepressants | 1444 |
| Bipolar I disorder | 52, 118, 414, 541, 635, 658 |
| Bipolar affective disorder | 658, 2396, 2428 |
| Bipolar depression | 658 |
| Bipolar disorder | 49, 434, 635, 658, 781, 805, 808, 810, 1210, 1258, 1991, 1997, 2003, 2009, 2062, 2096, 2100, 2158, 2162, 2167, 2188, 2398, 2476 |
| Bipolar mania | 635, 658, 781 |
| Birdshot chorioretinopathy | 2130 |
| Birth weight | 2306 |
| Birth weight and metal toxicity | 2128 |
| Bisallylic hydroxylation | 1669 |
| Bisphosphonate-related osteonecrosis in multiple myeloma | 1371 |
| Bladder cancer | 68, 164, 247, 494, 791, 844, 1094, 1235, 1240, 1282, 1307, 1338, 1450, 1670, 1903, 2027, 2109, 2203, 2239, 2251, 2294, 2297, 2470, 2498, 2507, 2518, 2527 |
| Bladder outlet obstruction | 1952 |
| Bladder overactivity | 202 |
| Bladder tumors | 791, 1240, 1903, 2251, 2290 |
| Blastocystis hominis infections | 391 |
| Blastomyces dermatitidis | 39, 514 |
| Blastomycosis | 310, 402, 407 |
| Bleeding disorder | 2325, 2439 |
| Blepharitis | 514 |
| Blepharospasm | 90 |
| Blood | 1670 |
| Blood lead levels | 1100 |
| Blood lipids | 1915, 2226 |
| Blood pressure | 1670, 1936, 2395 |
| Blood pressure regulation | 1225 |
| Blood-brain barrier | 844, 934, 1003, 1133, 1282, 1338, 1670 |
| Blood-testis barrier | 845 |
| Body bone mineral density | 2343 |
| Body mass index | 1080, 2154 |
| Body weight loss | 1082, 1468 |
| Bone and joint infections | 128, 129, 132, 133, 137, 138, 140, 162, 377, 740 |
| Bone development | 2071 |
| Bone fracture risk | 1261 |
| Bone infections | 140, 341, 377, 740 |
| Bone loss | 1952 |
| Bone marrow transplantation | 305, 845 |
| Bone metabolism | 1671 |
| Bone metastases of malignancy |
171 |
| Bone metastases of solid tumors |
806 |
| Bone mineral density | 18, 1044, 2036, 2043, 2206 |
| Bone morphogenetic protein-2 (BMP-2) | 1952 |
| Bone structural traits | 1133 |
| Bowel disease | 224, 592 |
| Brachytic2/ZmABCB1 | 846 |
| Bradyarrhythmias | 398 |
| Bradycardia | 265, 1450 |
| Bradycardia-induced long QT syndrome | 2231 |
| Brain | 846, 934, 1003, 1468, 1615, 1936, 1980 |
| Brain apolipoproteins | 1133 |
| Brain aromatase | 1952 |
| Brain arteriovenous malformations | 1047 |
| Brain cancer | 2294 |
| Brain CYP2B | 1359 |
| Brain CYP2D6 | 1451 |
| Brain CYP2E1 | 1597 |
| Brain CYP3A4 | 1672 |
| Brain injury | 1953 |
| Brain metabolism | 1496 |
| Brain microvessels | 1338 |
| Brain penetration | 846 |
| Brain serotonin receptor binding | 1447 |
| Brain steroidogenesis | 1953 |
| Brain tumors | 124, 436, 619, 845, 1672, 2527 |
| Brain white matter lesions | 1134 |
| Brain-derived neurotrophic factor | 1134 |
| Brainstem glioma | 124 |
| BRCA1/BARD1 complex | 1954 |
| Breast and endometrial carcinoma | 458 |
| Breast and other epithelial carcinomas | 1271 |
| Breast cancer | 42, 81, 146, 190, 237, 247, 267, 274, 281, 293, 316, 318, 349, 373, 404, 421, 473, 494, 511, 559, 562, 641, 715, 728, 756, 791, 792, 793, 846, 934, 981, 1003, 1027, 1054, 1089, 1094, 1107, 1113, 1194, 1206, 1208, 1214, 1221, 1230, 1233, 1235, 1237, 1249, 1261, 1263, 1282, 1307, 1338, 1371, 1382, 1402, 1408, 1452, 1597, 1672, 1954, 1999, 2016, 2024, 2027, 2036, 2043, 2105, 2109, 2115, 2119, 2151, 2156, 2188, 2213, 2222, 2239, 2247, 2261, 2271, 2286, 2294, 2299, 2307, 2333, 2336, 2411, 2416, 2432, 2436, 2441, 2444, 2448, 2470, 2480, 2487, 2496, 2504, 2507, 2510, 2526, 2527 |
| Breast cancer chemoprevention | 1955, 1954 |
| Breast cancer, invasive | 641, 715 |
| Breast cancer, susceptibility to | 1249, 1261, 1263, 1999, 2336 |
| Breast, head and neck, and lung carcinomas | 473, 792 |
| Breast-ovarian cancer | 1053 |
| Bronchial airway hyperactivity | 469 |
| Bronchial asthma | 157, 265, 266, 516, 726, 764 |
| Bronchial epithelial and alveolar macrophage cells | 1673 |
| Bronchial hyperresponsiveness | 2037 |
| Bronchitis | 136, 393, 745 |
| Bronchoconstriction | 328 |
| Bronchodilator | 664, 726, 750 |
| Bronchopulmonary dysplasia | 652, 750 |
| Bronchospasm | 265, 266, 313, 328, 393, 673, 745 |
| Brucellosis | 704 |
| Brugada syndrome | 2386, 2389 |
| Brunner syndrome | 2259 |
| Buccal mucosa carcinogenesis | 1903 |
| Budd-Chiari syndrome | 2049 |
| Bulimia nervosa | 317, 2475 |
| Burkitt’s lymphoma variant/acute lymphoblastic leukemia with translocations t(2;8)(p12;q24);t(8;22)(q24;q11) | 1025 |
| Burkitt’s lymphoma | 190, 967 |
| Burns | 15, 255, 287, 608, 610, 685, 699, 724 |
| Bursitis | 383, 764, 709, 724 |
| Buruli ulcer | 2401 |
| C | |
| Cachexia | 458, 699 |
| CADASIL | 2302 |
| Caffey disease | 1261 |
| CAG repeat polymorphisms | 1185 |
| Calcineurin inhibitor-induced chronic kidney disease | 1615 |
| Calcium deficiency | 110, 111, 113 |
| Calcium depletion | 110, 112 |
| Calcium oxalate calculi | 21 |
| Calcium supplementation | 112 |
| Camurati-Engelmann disease | 2444 |
| Cancer | 848, 1105, 1110, 1134, 1193, 1214, 1453, 1597, 1678, 1992, 2027, 2101, 2102, 2112, 2113, 2286, 2290, 2491, 2526 |
| Cancer chemotherapy | 977 |
| Cancer chemotherapy-induced nausea and vomiting | 506, 561, 620, 773 |
| Cancer metastasis | 1615 |
| Cancer pain | 301, 848, 2081 |
| Cancer risk | 2510 |
| Cancer susceptibility | 2369 |
| Candida infection | 39, 310, 725, 795 |
| Candidal cystitis | 39 |
| Candidemia | 43, 126, 310, 795 |
| Candidiasis | 407, 538, 603, 725, 726 |
| Candiduria | 407 |
| Cannabinoid receptor GPR55 | 934 |
| Capillary infantile hemangioma | 2236 |
| Carbamazepine hypersensitivity | 2157 |
| Carbonic anhydrase II | 1956 |
| Carbuncles | 287, 309 |
| Carcinogenesis | 1468 |
| Carcinoid syndrome | 703, 2268 |
| Carcinoid tumor | 703 |
| Carcinoid tumors, intestinal | 539 |
| Carcinoma | 849, 1615, 2090 |
| Carcinoma cells | 2328 |
| Carcinoma of the colon or rectum | 395 |
| Cardiac arrest | 266, 772, 1597 |
| Cardiac arrest and therapeutic hypothermia | 1597 |
| Cardiac arrhythmias | 449, 2229, 2386 |
| Cardiac bypass surgery | 772 |
| Cardiac CYP450s | 1283, 1615 |
| Cardiac decompensation | 206, 236 |
| Cardiac ischemic complications | 271 |
| Cardiac potassium channel KCNA5 | 849 |
| Cardiac resuscitation | 112 |
| Cardiac valve disease | 1134 |
| Cardiac valve replacement | 797 |
| Cardiofaciocutaneous syndrome | 1204, 2239 |
| Cardiomyopathy | 217, 2284, 2395, 2482 |
| Cardiomyopathy and deafness | 2284 |
| Cardiomyopathy with or without skeletal myopathy | 2285 |
| Cardiopulmonary bypass | 15, 218 |
| Cardiopulmonary bypass and coronary artery bypass grafting | 1134 |
| Cardiotoxicity | 1549, 1568 |
| Cardiovascular adverse events | 1454 |
| Cardiovascular disease | 57, 78, 1051, 1057, 1070, 1076, 1080, 1085, 1089, 1095, 1105, 1117, 1120, 1197, 1269, 1371, 1597, 1615, 1936, 1956, 2044, 2051, 2128, 2146, 2152, 2211, 2286, 2299, 2366, 2422, 2452 |
| Cardiovascular function | 1067, 1076, 2081 |
| Cardiovascular risk | 1447, 2053, 2366 |
| Cardiovascular status | 2316 |
| Carminative | 780 |
| Carotid atherosclerosis | 611, 2306 |
| Carotid endarterectomy | 1245 |
| Castration | 1683 |
| Cataplexy | 693 |
| Cataract surgery | 9, 409, 520, 624, 774 |
| Cauterization of wounds and sluggish ulcers | 684 |
| Caveolin-1-deficiency | 1936 |
| CCR5-tropic HIV-1 infection | 451 |
| CD34/M-cadherin bone marrow progenitor cells | 1134 |
| CD36 | 1134 |
| CD44 | 849 |
| CD147/basigin | 849 |
| CD 437 | 1235, 2062, 2137, 2238, 2347, 2472 |
| CD 4528 | 2516 |
| CDX2 (caudal-related homeobox transcription factor) | 849 |
| Celiac disease | 1274, 1684, 1907, 2139, 2199 |
| Cellulites | 309 |
| Central core disease | 2383 |
| Central hypoventilation syndrome | 2379 |
| Central nervous system infections | 39 |
| Central nervous system injury | 1257 |
| Central nervous system lymphoma | 1004 |
| Central obesity | 2316 |
| Centronuclear myopathy | 2383 |
| Cerebellar ataxia | 2334 |
| Cerebral amyloid angiopathy | 1134, 1169, 1936 |
| Cerebral contusion | 141 |
| Cerebral edema | 214, 450 |
| Cerebral infarction | 1907, 2060, 2365 |
| Cerebral malaria | 2455 |
| Cerebral microhemorrhage and vascular amyloid deposition | 1135 |
| Cerebral palsy | 65, 85, 90, 123, 200 |
| Cerebral vascular disease | 166, 342, 794 |
| Cerebral venous thrombosis | 797, 2048 |
| Cerebrooculofacioskeletal syndrome | 2031 |
| Cerebrooculofacioskeletal syndrome (type 1) | 2033 |
| Cerebrooculofacioskeletal syndrome 4 | 2029 |
| Cerebrotendinous xanthomatosis | 1684, 1915, 1981 |
| Cerebrovascular accident | 2513 |
| Cerebrovascular atherosclerosis | 611, 1135 |
| Cerebrovascular disorders | 523, 611, 1135, 1160, 1408 |
| Cerebrovascular insufficiency | 272 |
| Cervical cancer | 359, 755, 793, 1225, 2025, 2057, 2192, 2307, 2444, 2471 |
| Cervical dystonia | 91, 2007 |
| Cervical neoplasia | 755, 793, 2438 |
| Cervical/urethral gonorrhea | 131, 162, 540, 700, 731 |
| Cervicitis | 63, 540 |
| Cervicocerebral artery atherosclerosis | 1135 |
| Chagas’ disease | 2197 |
| Channelopathy-associated insensitivity to pain | 2390 |
| Chaperone | 1685 |
| Charcoal-broiled meat | 1685 |
| Chemical inhibitors of CYPs | 1455 |
| Chemically-induced carcinogenesis | 1598 |
| Chemokine (C-C motif) receptor 5-2459 genotype | 1360 |
| Chemokine receptor CCR6 | 1135 |
| Chemotherapeutics | 2307 |
| Chemotherapy-induced anemia | 202 |
| Chemotherapy-induced leukemia | 2115 |
| Chemotherapy-induced nausea and vomiting | 620, 773 |
| Chickenpox | 779 |
| Childhood acute lymphoblastic leukemia | 1283, 1598 |
| Childhood asthma | 672, 804 |
| Childhood leukemia | 2128 |
| Chitosan micellar system | 850 |
| Chlamydial infection | 147, 167, 168, 248, 276, 340, 700, 709, 731 |
| Chlamydophila pneumoniae | 719 |
| Chloroquine-resistant Plasmodium falciparum malaria | 616, 633, 638 |
| Cholangiocarcinoma | 850, 2092 |
| Cholera | 761 |
| Cholestasis | 749, 967, 1687, 1916, 2491 |
| Cholestatic liver disease | 2400 |
| Cholesterol | 823, 929, 996, 1116, 1120, 1161, 1169, 1182, 1187, 1215, 1242, 1687, 1932, 2188, 2245, 2250, 2253, 2300, 2312, 2314, 2337, 2385, 2446, 2465, 2516, 2519 |
| Cholesterol 25-hydroxylation activity of CYP3A | 1982 |
| Cholesterol efflux pathways | 990 |
| Cholesterol gallstone disease | 1916 |
| Cholesterol homeostasis in laboratory opossums (Monodelphis domestica) | 1981 |
| Cholesterol levels | 1058, 2088 |
| Cholesterol metabolism | 817 |
| Cholesterol-free mouse | 1916 |
| Cholesteryl ester transfer protein (CETP) | 990 |
| Cholesteryl oleyl ether | 2385 |
| Cholestenoic acid | 1981 |
| Cholic acid | 823, 929, 962, 964, 1215, 1687, 1916, 1932, 2019, 2150, 2183, 2194, 2198, 2208, 2217, 2253, 2337, 2446, 2458 |
| Cholic and chenodeoxycholic acid | 1233, 1687 |
| Choline acetyltransferase | 1135 |
| Choline-related organ dysfunction | 2332 |
| Chondrogenesis | 850 |
| Chorea | 729 |
| Choreiform syndrome | 1477 |
| Choriocarcinoma | 146, 791, 1004 |
| Chorionic gonadotropin | 990 |
| Christmas disease | 295 |
| Chromomycosis | 407 |
| Chromosomal damage | 2498 |
| Chromosomal damage and cancer risk | 2527 |
| Chromosome 5q deletion syndrome | 1271 |
| Chromosome fusion | 1956 |
| Chronic alcoholism | 235, 2405 |
| Chronic allograft nephropathy | 2455 |
| Chronic anal fissure | 90 |
| Chronic angina | 645 |
| Chronic anterior uveitis | 657 |
| Chronic asthma | 732, 801, 804, 1075 |
| Chronic bacterial prostatitis | 162 |
| Chronic bronchitis | 47, 168, 253, 340, 426, 540, 664, 745, 768 |
| Chronic bronchopulmonary disease | 9 |
| Chronic constipation | 413, 629, 631 |
| Chronic consumptive coagulopathy | 356 |
| Chronic diarrhea | 437 |
| Chronic eczematous external otitis | 314 |
| Chronic granulomatous disease | 390 |
| Chronic hepatitis | 1469 |
| Chronic hepatitis B virus infection | 12, 413, 718, 723, 2321 |
| Chronic hepatitis C | 570, 571, 652, 1598 |
| Chronic high-cholesterol diet | 1916 |
| Chronic idiopathic constipation | 443, 718 |
| Chronic idiopathic pancreatitis | 624 |
| Chronic idiopathic urticaria | 54, 142, 211, 425, 438 |
| Chronic immune thrombocytopenia | 2197 |
| Chronic iron overload | 206 |
| Chronic kidney disease | 109, 161, 206, 246, 292, 303, 566, 682, 817, 851, 2247, 2299, 2377 |
| Chronic kidney failure | 1031 |
| Chronic liver disease | 1489, 1982 |
| Chronic lung diseases | 732 |
| Chronic lymphocytic leukemia | 18, 71, 146, 167, 190, 311, 380, 540, 578, 661, 851, 2055 |
| Chronic mucocutaneous candidiasis | 407 |
| Chronic myelocytic leukemia | 190, 195, 367 |
| Chronic myelogenous leukemia | 103, 167, 204, 205, 373, 386, 387, 526, 734, 792, 1025 |
| Chronic myeloid leukemia | 172, 204, 525, 851, 935, 1004, 1026, 1196,1283, 2429 |
| Chronic myeloproliferative disorders | 2331 |
| Chronic nonspherocytic hemolytic anemia | 2078 |
| Chronic obstructive pulmonary disease (COPD) | 15, 31, 47, 58, 63, 77, 381, 393, 467, 664, 673, 745, 1254, 1266, 1274, 1283, 1309, 1338, 1351, 1598, 2021, 2207, 2247, 2297, 2343, 2527 |
| Chronic open-angle glaucoma | 79, 125, 233, 256, 423, 480 |
| Chronic pain | 301, 364 |
| Chronic pancreatitis | 1056 |
| Chronic periodontitis | 2203 |
| Chronic plaque psoriasis | 17, 108, 258, 284, 718 |
| Chronic Pseudomonas aeruginosa infection in cystic fibrosis | 748, 2056 |
| Chronic renal failure | 202, 211, 268, 269, 396 |
| Chronic rheumatoid arthritis | 226, 724, 738, 749, 752, 764, 812 |
| Chronic rhinitis | 556 |
| Chronic rhinosinusitis | 2270 |
| Chronic solid organ rejection | 613 |
| Chronic stable angina | 5, 34, 86, 229, 403, 523, 788 |
| Chronic suppurative otitis media | 540 |
| Chronic swelling | 214 |
| Chronic synovitis | 2133 |
| Chronic thromboembolic pulmonary hypertension | 797, 2138 |
| Chronic uremia | 1135 |
| Chronic urticaria | 551, 584 |
| Circadian regulation | 1916 |
| Circadian rhythm sleep disorders | 2289 |
| Circulating thymic factor | 2208 |
| Cirrhosis | 701, 754, 1688, 2128, 2444 |
| Cisplatin-induced renal toxicity | 28 |
| Citrobacter rodentium infection | 1598 |
| Classic subfoveal choroidal neovascularization | 790 |
| Claudin-7-deficiency | 1936 |
| Cleft lip/palate | 1220, 2287, 2291 |
| Clopidogrel and proton pump inhibitors | 1410 |
| Cloning | 1693 |
| Clonorchiasis | 612 |
| Clubfoot | 1283, 1310 |
| Cluster headache | 711, 755 |
| Clusterin | 1135 |
| c-Myc | 852 |
| CNS drugs | 1532 |
| CNS-active drugs | 1598 |
| CNS infections | 483, 549 |
| CNS leukemia/lymphoma | 737 |
| CNS metastases | 736 |
| CNS pathology-associated risk factors | 1128 |
| Coarctation of aorta | 24 |
| Cocaine abuse | 2000 |
| Cocaine-related disorders | 1258 |
| Coccidioides immitis | 39 |
| Coccidioidomycosis | 310, 407 |
| Cochlea and organ of Corti | 1004 |
| Cockayne syndrome (type B) | 2033 |
| Cockayne syndrome, photosensitive trichothiodystrophy, and xeroderma pigmentosum/cockayne syndrome complex | 2031 |
| Codeine dependence | 1459 |
| Coelenterazine- and D-luciferin-based bioluminescence | 852, 935 |
| COG112 ApoE-mimetic peptide | 1136 |
| Cognition | 1050, 2167, 2170 |
| Cognition and prefrontal cortex function | 2099 |
| Cognition disorders | 794 |
| Cognitive deterioration | 794, 1957 |
| Cognitive dysfunction | 794 |
| Cognitive function | 675, 1136, 1459, 2009 |
| Colchicine resistance | 853 |
| Cold stress | 1917 |
| Cold-induced CYP1A activation | 1283, 1310 |
| Colitis | 1283 |
| Collagen diseases | 42, 613 |
| Colon adenoma | 1696 |
| Colon cancer | 316, 421, 436, 549, 631, 935, 1110, 1211, 1230, 1917, 2192, 2281, 2287, 2361, 2393, 2487, 2518 |
| Colon cancer, advanced | 549, 642 |
| Colonic evacuation | 680, 694 |
| Colonic neoplasms | 964, 1209, 2365, 2483 |
| Colorectal adenocarcinoma | 2251 |
| Colorectal adenoma | 1383, 1917, 2207 |
| Colorectal cancer | 115, 494, 549, 642, 704, 817, 853, 1005, 1054, 1058, 1105, 1113, 1203, 1204, 1211, 1221, 1269, 1283, 1310, 1339, 1459, 1598, 1696, 1957, 1982, 2021, 2029, 2031, 2044, 2084, 2109, 2115, 2119, 2128, 2176, 2188, 2190, 2219, 2225, 2240, 2247, 2271, 2277, 2291, 2294, 2297, 2333, 2341, 2343, 2360, 2369, 2380, 2412, 2415, 2438, 2444, 2448, 2452, 2471, 2480, 2498, 2501, 2515, 2527 |
| Colorectal cancer, susceptibility to | 1058, 1269, 2291 |
| Colorectal liver metastases | 1696 |
| Colorectal polyps | 1095, 2369 |
| Colorectal tumor | 642, 1058, 1269, 2291 |
| Combined deficiency of vitamin K-dependent clotting factors | 2083 |
| Comedications | 1957 |
| Common cold | 144, 630, 771 |
| Common variable immunodeficiency | 380, 2203 |
| Community-acquired pneumonia | 129, 130, 134, 135, 167, 168, 275, 426, 430, 503, 540, 719 |
| Comparative studies | 1477, 1481, 1487, 1496, 1502, 1510, 1522, 1523, 1525, 1531, 1550, 1557, 1568, 1578, 1696 |
| Complement | 1599 |
| Complement C5a inhibitors | 1137 |
| Complement receptor 1 (CR1) | 1137 |
| Complex absence seizures | 781 |
| Complex partial seizures | 781 |
| Compulsive craving during alcohol withdrawal | 1957 |
| Concurrent primary aldosteronism and subclinical cortisol hypersecretion | 1936 |
| Condylomata acuminata | 387, 388 |
| Connective tissue-activating peptide | 2323 |
| Conformational changes and ligand promiscuity | 1699 |
| Congenital adrenal hyperplasia (P450 oxidoreductase deficiency) | 1383, 1459, 1957 |
| Congenital afibrinogenemia | 2060 |
| Congenital agammaglobulinemia | 380 |
| Congenital bilateral absence of the vas deferens | 1247 |
| Congenital cardiac disease | 2287 |
| Congenital corneal opacification infantile glaucoma and von Hippel’s ulcer | 1339 |
| Congenital disorders of glycosylation type I | 2426 |
| Congenital glaucoma | 1339 |
| Congenital heart disease | 24, 652, 2297 |
| Congenital hyperinsulinism | 981, 2233 |
| Congenital hypoaldosteronism and sensorineural hearing loss | 1937 |
| Congenital myasthenic syndrome associated with episodic apnea | 1249 |
| Congenital mysathenic syndromes | 1252 |
| Congenital pancreatic hypoplasia and pancreatic agenesis | 982 |
| Congenital sucrase-isomaltase deficiency | 671 |
| Congestive heart failure | 8, 227, 331, 355, 361, 362, 380, 476, 520, 533, 651, 757, 1068, 1218 |
| Congestive heart failure, susceptibility to | 1068 |
| Conjunctival congestion | 731 |
| Conjunctivitis | 121, 162, 214, 337, 410, 514, 613, 707 |
| Constipation | 85, 447, 631, 680 |
| Constitutive androstane receptor (CAR) | 854, 1699 |
| Contraception | 710 |
| Conventional phenotyping | 1506 |
| Conversion of cholesterol into bile acids | 1917 |
| Convulsive disorders | 220 |
| Convulsive states | 332, 734 |
| Co-prescription of CYP2D6/3A4 inhibitor-substrate pairs | 1700 |
| Corneal edema | 691 |
| Corneal epithelium | 1005 |
| Corneal injury | 214, 316, 613, 1107 |
| Corneal ulcer | 162, 426, 613, 707 |
| Coronary arteriosclerosis | 610, 611, 2253 |
| Coronary artery aneurysms | 380 |
| Coronary artery bypass graft surgery | 610, 611, 739 |
| Coronary artery disease (CAD) | 442, 610, 611, 817, 977, 991, 1031, 1048, 1058, 1076, 1110, 1119, 1137, 1371, 1383, 1410, 1599, 1616, 1917, 1925, 2036, 2092, 2109, 2192, 2245, 2256, 2287, 2299, 2325, 2336, 2441 |
| Coronary artery disease in familial hypercholesterolemia, protection against | 442, 610, 611, 686 |
| Coronary artery disease, autosomal dominant, 1 | 610, 611 |
| Coronary artery disease, autosomal dominant, 2 | 610, 611 |
| Coronary artery disease, modifier of | 610, 611 |
| Coronary artery disease, resistance to | 610, 611 |
| Coronary artery disease, susceptibility to | 610, 611, 1076, 2092, 2336 |
| Coronary artery stenting | 271, 610 |
| Coronary atherosclerosis | 610, 611, 2152, 2225, 2277, 2336 |
| Coronary disease | 79, 610, 611, 1117, 1244, 1269, 2049, 2336 |
| Coronary heart disease | 339, 610, 611, 686, 1056, 1085, 1090, 1269, 1616, 2176, 2215, 2277, 2287, 2304 |
| Coronary heart disease, susceptibility to, 2 | 610, 611 |
| Coronary heart disease, susceptibility to, 3 | 610, 611 |
| Coronary heart disease, susceptibility to, 4 | 610, 611 |
| Coronary heart disease, susceptibility to, 6 | 610, 611 |
| Coronary heart disease, susceptibility to, 7 | 610, 611 |
| Coronary heart disease, susceptibility to, 8 | 610, 611 |
| Coronary heart disease, susceptibility to, 9 | 610, 611 |
| Coronary occlusion | 6, 610 |
| Coronary restenosis | 610 |
| Coronary revascularization | 610 |
| Coronary spasm | 610, 611, 2299 |
| Coronary spasms, susceptibility to | 610, 611 |
| Coronary stenosis | 610, 1137 |
| Coronary stent implantation | 610, 740, 1700 |
| Coronary thrombosis | 610, 611, 722 |
| Coronary vasospasm (coronary spastic angina) | 610, 611, 1137 |
| Corpus luteum | 1616 |
| Corticobasal degeneration | 1137 |
| Corticosteroid-responsive dermatosis | 16, 170, 226, 353, 354, 363, 613 |
| Corticosterone methyloxidase deficiency | 1937 |
| Corynebacterium infections | 337 |
| Cough | 219, 249, 351, 362, 393 |
| Coumarin 7-hydroxylation | 1351 |
| Coumarin resistance | 2521 |
| Courtship behavior | 1957 |
| CpG methylation | 1311 |
| CpG ODN 2006 | 2184, 2208, 2217, 2446, 2458 |
| CPG-oligonucleotide | 2371 |
| C-Reactive protein | 1937 |
| Cramps | 60, 780 |
| Craniocerebral trauma | 141 |
| Creutzfeldt-Jakob disease | 1137, 2349 |
| Cri-du-chat syndrome | 2441 |
| Crigler-Najjar’s syndrome | 2487, 2496 |
| CRIM1 | 855 |
| Crohn’s disease | 11, 97, 141, 384, 514, 732, 855, 1085, 1225, 1258, 1271, 1274, 1701, 1907, 2058, 2207, 2215, 2219, 2311, 2362, 2452, 2466 |
| Crohn’s disease-associated growth failure | 2207 |
| Cryopreserved human hepatocytes | 1701 |
| Cryopyrin-associated periodic syndromes | 113, 656 |
| Cryptococcal meningitis | 310 |
| Cryptococcus neoformans | 39 |
| Cryptorchidism | 1185 |
| CUGBP2 | 1137 |
| Cushing’s syndrome | 30, 214, 1702 |
| Cutaneous and mucosal leishmaniasis | 2212 |
| Cutaneous candidiasis | 158, 177, 256, 407, 538 |
| Cutaneous dermatophytoses | 407, 610, 613 |
| Cutaneous drug-metabolizing enzymes | 1402 |
| Cutaneous larva migrans | 733 |
| Cutaneous leishmaniasis | 2452 |
| Cutaneous malignant melanoma | 1204, 1235 |
| Cutaneous melanoma | 2515 |
| Cutaneous T-cell lymphoma | 208, 608, 664, 796 |
| Cutaneous/gastrointestinal/oropharyngeal anthrax | 426 |
| CXCL16 | 1138 |
| CXCRs | 1005 |
| Cyanide poisoning | 41, 366, 477, 695 |
| Cyclic AMP | 1247, 1259, 2150, 2154, 2155, 2194, 2220, 2346 |
| Cyclic GMP | 967, 971, 1088, 1106, 2300, 2305, 2371, 2458 |
| Cyclin D1 | 1957 |
| Cyclin-dependent kinase 2 | 1702 |
| Cyclin-dependent kinase inhibitors | 855, 1702 |
| Cyclooxygenase-2 | 856, 1005 |
| Cyclooxygenases (COX-1, COX-2) | 968 |
| Cyclophosphamide in breast cancer | 1360 |
| Cyclophosphamide in lupus nephritis | 1361 |
| Cycloplegia | 59, 190 |
| CYP induction | 1361 |
| CYP inhibitors | 1412, 1460, 1599, 1712 |
| CYP phosphorylation | 1712 |
| CYP17 inhibitors | 1712 |
| CYP1A1 expression | 1284 |
| Cyp1a1-Ren-2 transgenic rats | 1284 |
| CYP1A2 induction | 1311 |
| CYP1A2 metabolism screening | 1311 |
| Cyp2a5-null mouse | 1351 |
| CYP2A6 variants | 1351 |
| CYP2A13 and lung cancer | 1352 |
| CYP2C induction | 1403 |
| CYP2C P450 enzymes in human hepatocytes | 1705 |
| CYP2C18-19 humanized mice | 1402 |
| CYP2D6 and antidepressant switching | 1445 |
| CYP2D6 in Alzheimer’s disease | 1442 |
| CYP2D6-CYPOR | 1460 |
| CYP2D6-NADPH cytochrome P450 reductase fusion protein | 1705 |
| CYP2D6-related biochemical and hemodynamic phenotypes in Alzheimer’s disease | 1442 |
| CYP2D6-related therapeutic response to a multifactorial treatment | 1442 |
| CYP2J2 inhibitors | 1616 |
| CYP2J2 substrates | 1617 |
| CYP3A cluster (CYP3A4, CYP3A5, CYP3A7, CYP3A43) | 1705 |
| CYP3A isozyme ligands | 1708 |
| CYP3A4 5′ promoter variants | 1709 |
| CYP3A4 5′ regulatory region | 1707 |
| CYP3A4 catalytic specificity | 1705 |
| CYP3A4 degradation | 1706 |
| CYP3A4 induction | 1708 |
| CYP3A4 inhibitors | 1708 |
| CYP3A4 multiple substrate binding | 1709 |
| CYP3A4 oxidation | 1709 |
| CYP3A4 transactivation | 1710 |
| CYP3A4 vs CYP3A5 | 1706 |
| CYP3A4*20 (CYP3A4 allele without functional activity) | 1706 |
| CYP3A4/5/7 gene expression | 1707 |
| CYP3A4/5/7 gene expression in cancer | 1707 |
| CYP3A4-ABCB1 (MDR1) interactions | 1708 |
| CYP3A4-CYP2C8 interactions | 1706 |
| CYP3A4-CYP2D6 interactions in psychiatric patients | 1706 |
| CYP3A4-PXR relationship | 2311 |
| CYP3A4-UDP-glucuronosyltransferase activity | 1710 |
| Cys11-Cys15-endothelin-1 (11-21) | 2013 |
| Cystic fibrosis | 9, 242, 748, 935, 1247, 1460, 1712, 2192, 2444 |
| Cystic fibrosis lung transplant | 1412 |
| Cystic fibrosis pulmonary disease | 2014 |
| Cystic hydatid disease | 14 |
| Cystic tumors | 764 |
| Cysticercosis | 612 |
| Cystine-based glutathion precursor (F1 antioxidant) | 1138 |
| Cystinuria | 574 |
| Cystitis | 162, 307 |
| Cytochrome b5 | 1460, 1713 |
| Cytochrome C oxidase deficiency | 2281 |
| Cytochrome P450 1A1 gene transcription | 2109 |
| Cytochrome P450 oxidoreductase | 1312, 1460, 1957 |
| Cytochrome P450 oxidoreductase deficiency | 1957 |
| Cytochrome P450 oxidoreductase deficiency and Antley-Bixler craniosynostosis syndrome | 1957 |
| Cytochrome P450 reductase | 1713 |
| Cytochrome P450 time-dependent inhibition assays | 1713 |
| Cytokine-induced killer (CIK) cell | 856 |
| Cytomegalovirus | 818 |
| Cytomegalovirus disease | 195, 780 |
| Cytomegalovirus infections | 336, 780 |
| Cytomegalovirus retinitis | 158, 330, 336, 780 |
| Cytokines | 936, 1403, 1713 |
| Cytotoxic ribonuclease PE5 | 857 |
| D | |
| Dandruff | 179, 407, 672, 679 |
| Dap1/PGRMC1 | 1624, 1714 |
| de novo Acute leukemia | 1006 |
| De Sanctis-Cacchione syndrome | 2033 |
| Death | 1524 |
| Decreased viability among fetuses | 2287 |
| Deep venous thrombosis | 199, 327, 703, 744, 797, 1384, 2048, 2299 |
| Defective control of prolactin secretion | 628 |
| Defective CYP3A4 and CYP3A5 SNPs | 1715 |
| Deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase | 693 |
| Deficiency of the prothrombin complex coagulation factors II, VII, IX, and X | 628 |
| Degenerative disc disorder | 2081 |
| Degree of CYP450 enzyme inhibition of antidepressant drugs at their usual therapeutic dose | 1444 |
| Dehydration | 220 |
| Delayed male puberty | 728 |
| Delayed puberty | 349 |
| Delayed sleep phase syndrome | 1273 |
| Delirium | 301, 589, 1138 |
| Delta-storage pool deficiencies | 968 |
| Dementia | 277, 662, 713, 750, 1170 |
| Dementia of the Alzheimer’s type | 662, 713, 750, 1170 |
| Dementia syndromes | 342 |
| Demyelinating diseases | 380 |
| Dengue disease | 2130, 2438 |
| Dengue hemorrhagic fever | 2444 |
| Dental caries | 315 |
| Dental expression | 1006 |
| Dental pain | 321 |
| Depression | 33, 37, 165, 210, 245, 378, 396, 450, 485, 493, 497, 516, 537, 583, 609, 629, 702, 710, 762, 770, 791, 857, 1138, 1263, 1265, 1266, 1412, 1461, 2062, 2092, 2162, 2163, 2287, 2369, 2395, 2396, 2417, 2520 |
| Depressive disorder | 609, 648, 1266, 2165 |
| Depressive emotional conditions | 342 |
| Dermatitis | 314, 672 |
| Dermatitis herpetiformis | 201 |
| Dermatologic diseases | 613, 764 |
| Dermatophytes | 725, 776 |
| Dermatophytoses | 35, 177, 256 |
| Dermatosis | 212, 217, 322, 350, 407, 499 |
| Des-Arg9-Bradykinin | 2459 |
| Desmoid disease | 1113 |
| Desmoid tumor | 791 |
| Dexmedetomidine anesthesia | 959, 1066, 1930 |
| Developmental changes | 1461 |
| Developmental delay, epilepsy and neonatal diabetes syndrome | 2233 |
| Deviant anti-social sexual behavior | 71 |
| Diabetes | 631, 936, 1372, 1958, 1983, 2197, 2261, 2339 |
| Diabetes and food intake | 1477 |
| Diabetes and insulin resistance syndrome | 2343 |
| Diabetes insipidus | 211, 785 |
| Diabetes mellitus | 79, 610, 818, 982, 991, 1076, 1081, 1117, 1138, 1214, 1240, 1269, 1384, 1462, 1617, 1718, 2037, 2211, 2235, 2281, 2415, 2483, 2501 |
| Diabetes mellitus (type 1 and type 2) | 1226 |
| Diabetes mellitus (type 1) | 385, 610, 1049, 1058, 1233, 2130, 2134, 2138, 2140, 2143, 2180, 2219, 2299, 2445 |
| Diabetes mellitus (type 2) | 293, 344, 345, 346, 394, 610, 649, 667, 676, 689, 1066, 1076, 1081, 1086, 1235, 1269, 2053, 2088, 2093, 2101, 2248, 2290, 2478, 2529 |
| Diabetes mellitus, insulin-dependent | 610 |
| Diabetes mellitus, noninsulin-dependent | 4, 610, 649, 667, 676, 689, 750, 751 |
| Diabetes, susceptibility to | 2290 |
| Diabetic gastric stasis | 481 |
| Diabetic gastroparesis | 240 |
| Diabetic ketoacidosis | 385 |
| Diabetic macrovascular disease (type 1) | 1983 |
| Diabetic nephropathy | 117, 252, 394, 441, 636, 1086, 1138, 1983, 2109, 2192, 2235, 2346, 2422 |
| Diabetic nephropathy (type 2) | 636, 2215 |
| Diabetic neuralgia | 118 |
| Diabetic neuropathic ulcers | 68 |
| Diabetic neuropathy | 116, 615 |
| Diabetic retinopathy | 2336, 2346 |
| Diabetic vascular disease | 2153 |
| Diagnostic procedures | 773 |
| Diagnostic test | 775, 785 |
| Diaper rash | 144, 805 |
| Diarrhea | 60, 86, 144, 155, 412, 480, 519, 529, 565, 601, 671 |
| Diarrhea-predominant irritable bowel syndrome | 22, 1066 |
| Diazoxide-responsive hyperinsulinemic hypoglycemia | 982, 2149 |
| Dicer-related liver zonation | 1599 |
| Diet | 1720 |
| Dietary factors | 1720 |
| Dietary fiber supplement | 631 |
| Dietary rice protein | 1139 |
| Dietary sodium intake | 1937 |
| Dietary supplement | 111, 112, 113, 145, 154, 446, 447, 750, 795, 1139 |
| Diffuse large B-cell CD20-positive NHL | 661, 757 |
| Diffuse large B-cell lymphoma | 2528 |
| Diffuse panbronchiolitis | 1720 |
| Dihydropyrimidinase deficiency | 1996 |
| Dihydropyrimidine dehydrogenase deficiency | 1995 |
| Dihydrotestosterone (DHT) | 1027, 1098, 1099, 1102, 1103, 1161, 1182, 1187, 1194, 1220, 1222, 1233, 1978, 2040, 2072, 2177, 2188, 2253, 2312, 2345, 2352, 2376, 2446, 2453, 2459, 2519 |
| Dilated cardiomyopathy | 1068, 1071, 1073, 2354, 2358 |
| Diphtheria | 255, 276 |
| Discoid lupus erythematosus | 732, 764 |
| Disinfection of utensils and equipment | 692 |
| Disseminated candidiasis | 310 |
| Distal hereditary motor neuropathy | 1193 |
| Distal interphalangeal joint osteoarthritis | 2192 |
| Distal myopathy | 2334 |
| Diuretic non-responders with non-azotemic cirrhosis and ascites | 1937 |
| Diverticulitis | 677 |
| Dizziness | 255 |
| DNA hypomethylation | 983 |
| DNA methylation and Epigenetic phenomena | 859 |
| DNA microarray technology | 1723 |
| DNA repair | 1600 |
| Dominant beta-thalassemia inclusion body type | 2125 |
| Dopa-responsive dystonia | 2081 |
| Double-transduced MDCKII Cells | 861 |
| Down’s syndrome | 991, 1170, 2287, 2291 |
| Doxorubicin and cyclophosphamide in breast cancer | 1361 |
| Doxycycline-inducible, tissue-specific aromatase-expressing transgenic mouse | 1958 |
| Dracunculiasis | 733 |
| Drinking behavior | 1600 |
| Drug addictions | 166 |
| Drug biotransformation | 1725 |
| Drug disposition | 1007 |
| Drug oxidation | 1464 |
| Drug transporters and phase I and II metabolism | 1725 |
| Drug-associated torsades de pointes, LQTS and arrhythmia | 2229, 2231 |
| Drug-induced extrapyramidal symptoms | 26, 621, 767 |
| Drug-induced liver injury | 1385, 1725 |
| Drug-induced methemoglobinemia | 477 |
| Drug-induced osteoporosis | 1958 |
| Drug-induced torsade de pointes | 2231 |
| Drug-resistant tuberculosis | 286 |
| Drugs of abuse | 1007 |
| Drug-virus interaction | 1725 |
| Dry eye syndrome | 367 |
| Ductal carcinoma | 715 |
| Ductus arteriosus | 24, 383 |
| Duodenal ulcer | 160, 279, 296, 415, 534, 545, 640, 645, 706, 710 |
| Dutch familial combined hyperlipidemia | 2466 |
| Dynamic equines foot deformity | 90 |
| Dysfunctional uterine bleeding | 349 |
| Dyskeratosis congenita | 2441 |
| Dyslipidemia | 57, 299, 522, 597, 675, 1726, 1918, 2052, 2054, 2292 |
| Dysmenorrhea | 5, 265, 371, 455, 780 |
| Dysphagia | 399 |
| Dysprothrombinemia | 2048 |
| Dysuria | 307 |
| E | |
| E. coli infection | 39, 119, 128, 594 |
| Early-onset diabetes (type 2) | 1251 |
| Eating disorders | 1465, 2167 |
| Eclampsia | 449 |
| Ecto-5′-nucleotidase and thiopurine | 968 |
| Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) | 1139 |
| Ectopic calcification | 287 |
| Eczema | 255 |
| Edema | 8, 98, 150, 153, 285, 333, 362, 381, 476, 613, 701, 2377 |
| Edematous states | 29, 613 |
| Efferocytosis | 818 |
| Ehlers-Danlos syndrome | 1261 |
| Ehrlichiosis | 1727 |
| Elderly | 1535, 1558 |
| Electrolyte replacement | 448 |
| Electrolytes | 1248 |
| Embolism | 356, 797 |
| Embryonic carcinoma | 1007 |
| Emergency contraception | 427 |
| Emetogenic cancer chemotherapy | 46 |
| Emphysema | 47, 253, 393, 745, 1904, 2021 |
| Empiric antifungal therapy | 795 |
| Endobronchial non-small cell lung cancer | 1968 |
| Endocarditis | 309, 310, 341, 377, 704 |
| Endocrine disorders | 613, 764 |
| Endoglin | 1139 |
| Endometrial cancer | 190, 456, 1285, 1314, 1335, 1728, 1958, 2023, 2044, 2432 |
| Endometrial hyperplasia | 456, 621 |
| Endometrioid adenocarcinomas | 1045 |
| Endometriosis | 101, 200, 349, 422, 508, 535, 864, 1095, 1412, 1958, 1965, 1983, 2156, 2176, 2518 |
| Endometriosis-associated pain | 456 |
| Endoscopic retrograde cholangiopancreatography visualization | 678 |
| Endothelial nitric oxide synthase | 1340 |
| Endothelin-1 | 991 |
| Endothelin-1 receptor antagonists | 864 |
| Endotracheal intubation | 58, 164, 646, 663, 705 |
| End-stage renal disease | 416, 1937, 2037 |
| Engraftment syndrome | 1007 |
| Enteric fever | 1247 |
| Enteric rods | 162 |
| Enteritis | 769 |
| Enterobacter infection | 39, 119 |
| Enterocutaneous and rectovaginal fistulas | 384 |
| Enuresis | 211, 265 |
| Enzyme kinetics | 1729 |
| Ependymoma | 124, 864, 1007 |
| Epicondylitis | 764 |
| Epidermal growth factor receptor 2-positive metastatic breast cancer | 760, 1959 |
| Epidermal nevus | 2240, 2333 |
| Epidermis | 1959 |
| Epidermophyton infections | 725 |
| Epigenetics | 1340, 1729, 1959 |
| Epilepsy | 170, 220, 333, 463, 808, 864, 1140, 1253, 1285, 1385, 1413, 1465, 1729, 2349, 2385, 2386, 2387, 2467 |
| Epilepsy with generalized tonic-clonic seizures | 220, 584, 588 |
| Epilepsy with grand mal seizures on awakening | 617 |
| Epilepsy, generalized idiopathic | 1253 |
| Epilepsy, juvenile myoclonic | 1253 |
| Epileptic seizures | 118 |
| Episcleritis | 457 |
| Episiotomies | 798 |
| Epithelial keratitis | 767 |
| Epithelial ovarian cancer, somatic | 460 |
| Erectile dysfunction | 24, 684, 715, 783, 1730, 2092, 2299 |
| ERK1 and ERK2 MAPKs | 1314 |
| Erosive esophagitis | 279, 415, 545, 645, 1413, 1420 |
| Erythema multiforme | 732 |
| Erythema nodosum leprous | 732 |
| Erythrasma | 276 |
| Erythromycin breath test | 1731 |
| Erythropoietic protoporphyria | 77 |
| Escherichia coli infection | 39, 119, 128, 594 |
| Esophageal achalasia | 90 |
| Esophageal adenocarcinoma | 1959 |
| Esophageal cancer | 603, 866, 1007, 1054, 1105, 1240, 1386, 1600, 2115, 2130, 2134, 2369, 2471, 2518 |
| Esophageal candidiasis | 310, 486, 795 |
| Esophageal mucosa and nitrosamine metabolism | 1732 |
| Esophageal spasms | 399 |
| Esophageal squamous cell carcinoma | 1352, 1732 |
| Esophageal varices | 696, 785 |
| Esophagitis | 215, 296 |
| Essential fatty acid deficiency | 699, 1919 |
| Essential hypertension | 114, 229, 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 1035, 1063, 1066, 1068, 1071, 1077, 1081, 1197, 1937, 2007, 2023, 2093, 2143, 2380, 2415 |
| Essential tremor | 617, 626, 2003 |
| Estradiol deficiency | 1959 |
| Estrogen receptor alpha | 1413 |
| Estrogen receptor beta modulator 8β-VE2 | 1140 |
| Estrogen receptor beta signaling | 1007 |
| Estrogen receptor mutant (temperature-sensitive) | 2037 |
| Estrogen receptor mutations | 1960 |
| Estrogen receptor-positive breast cancer | 756, 1960 |
| Estrogen replacement therapy | 1140 |
| Estrogen resistance | 2037 |
| Estrogen-related receptor gamma (ERRG) | 1960 |
| Estrous cycle | 1600 |
| Ethanol dependence | 510 |
| Ethanol metabolism | 1107 |
| Ethanol withdrawal | 220, 552 |
| Ethnic differences | 866, 936, 968, 978, 1008, 1140, 1286, 1314, 1352, 1362, 1373, 1386, 1403, 1413, 1471, 1601, 1618, 1734, 1960 |
| Euvolemic and hypervolemic hyponatremia | 184, 754 |
| Evacuation of bowel | 680, 694 |
| Evolution of CYP3A4 expression variability | 1739 |
| Ewing’s sarcoma | 190, 198, 867, 1008 |
| Ex3α ERKO male infertility | 1960 |
| Excitability | 359, 702, 780 |
| Exercise-induced asthma | 2257 |
| Exercise-induced bronchospasm | 187, 673 |
| Exercise training | 2346 |
| Exfoliation glaucoma | 2251 |
| Exogenous obesity | 74, 225, 470 |
| Experimental autoimmune neuritis | 1142 |
| Experimental colitis | 1919 |
| Experimental venous thrombosis | 1938 |
| Extensive metabolizers (EMs) | 1506 |
| External genital and perianal warts secondary to Condylomata acuminate | 687 |
| Extra-adrenal 21-hydroxylation | 1739 |
| Extraintestinal amebiasis | 149 |
| Extrapyramidal side-effects | 1549 |
| Extrapyramidal symptoms | 1488 |
| Eye irritations | 276 |
| F | |
| Fabry disease | 13 |
| Facial dermatoses | 613 |
| Facial lipoatrophy | 601 |
| Facial mottled hyper-/hypopigmentation | 718 |
| Facial skin wrinkling | 718 |
| Factor V deficiency | 2049 |
| Factor VII deficiency | 295, 2051 |
| Factor IX deficiency | 295 |
| Fallot’s tetralogy | 24 |
| Familial adenomatous polyposis | 139, 1113, 2068 |
| Familial Alzheimer’s disease | 1165, 2263, 2355, 2358 |
| Familial atrial fibrillation | 2235 |
| Familial atrial fibrillation 3 | 2235 |
| Familial atrial fibrillation 4 | 2230 |
| Familial atrial fibrillation 6 | 2305 |
| Familial cold autoinflammatory syndrome | 113, 656 |
| Familial combined hyperlipidemia | 2054 |
| Familial dysbetalipoproteinemia | 611, 1132 |
| Familial febrile convulsions, 3 | 2385 |
| Familial hemiplegic migraine-3 | 2386 |
| Familial hyperaldosteronism | 1938 |
| Familial hyperaldosteronism type 1 | 1938 |
| Familial hypercholesterolemia | 611, 686, 818, 991, 1119, 2245 |
| Familial hyperinsulinemic hypoglycemia 1 | 983 |
| Familial hyperinsulinemic hypoglycemia 2 | 2233 |
| Familial hyperinsulinism | 983 |
| Familial hyperproreninemia | 2377 |
| Familial hypertriglyceridemia | 611 |
| Familial hypobetalipoproteinemia | 1119 |
| Familial hypocalciuric hypercalcemia | 1212 |
| Familial juvenile glaucoma | 1341 |
| Familial male-limited precocious puberty (testotoxicosis) | 1961 |
| Familial Mediterranean fever | 181 |
| Familial medullary thyroid carcinoma | 2379 |
| Familial melanoma | 619 |
| Familial mild hyperglycemia | 983 |
| Familial partial lipodystrophy (type 3) | 2343 |
| Familial/Primary hyperaldosteronism type I | 1938 |
| Fanconi’s anemia | 1209 |
| Fas receptor | 1739 |
| Fatal familial insomnia | 2349 |
| Fatigue | 343 |
| Fatty acid metabolism and metabolic diseases | 1908 |
| Fatty liver (Hepatic steatosis) | 1120, 1489, 2292, 2311 |
| Favism | 2077 |
| Febrile granulocytopenic patients | 135 |
| Febrile neutropenia | 126, 131, 162 |
| Febrile seizures | 2385 |
| Female genital neoplasm | 2432 |
| Female infertility | 326, 462 |
| Fertility | 1140 |
| Fertility status in endometriosis | 1961 |
| Fetal alcohol syndrome | 1054 |
| Fetal and newborn complications | 1535 |
| Fetal drug exposure | 868 |
| Fetal hydantoin syndrome | 2021 |
| Fetal tissues | 1618 |
| Feto-placental unit | 1741 |
| Fetoprotection | 1008 |
| Fever | 7, 53, 234, 371, 673 |
| Fibrillation | 372 |
| Fibrinogen plasma levels | 2060 |
| Fibrinolysis | 30 |
| Fibroblast growth factor 15/19 | 1919 |
| Fibroblast growth factor receptor 4 | 1920 |
| Fibrocystic breast disease | 200 |
| Fibroids | 600 |
| Fibrolamellar hepatocellular carcinoma | 1961 |
| Fibromyalgia | 251, 490, 615, 1141, 1263 |
| Fibrosarcoma | 196 |
| Fibrositis | 702 |
| Fibrotic and inflammatory lung diseases | 1601 |
| Fibrous dysplasia | 2071 |
| First-pass hepatic and intestinal biotransformation | 1742 |
| FK506-binding protein | 1742 |
| Flinders sensitive line rat model of depression | 1315 |
| FLT3-Internal tandem duplication | 2063 |
| Flucloxacillin-induced liver injury | 2126 |
| Fluorouracil resistance | 1114 |
| Flutter | 618, 626, 637 |
| Focal segmental glomerulosclerosis | 1938 |
| Folate homeostasis | 1745 |
| Follicular carcinoma of the thyroid gland | 1993 |
| Follicular non-Hodgkin lymphoma | 370, 387, 757 |
| Folliculitis | 309 |
| Food consumption | 2396 |
| Food intake | 1141 |
| Food-drug interactions | 1745 |
| Forensic toxicology | 1746 |
| Forkhead box transcription factor O1 | 1920 |
| Fragile X syndrome | 2069 |
| Fragile X-associated tremor/ataxia syndrome | 2069 |
| Fredrickson type IIa, IIb, and IV hyperlipidemias | 182, 667 |
| Fredrickson type III hyperlipidemia | 667 |
| Freezing human liver microsomes | 1746 |
| Friedreich’s ataxia | 373 |
| Frontotemporal dementia | 2349, 2356 |
| Frontotemporal dementia with parkinsonism linked to chromosome 17 | 2264 |
| Frontotemporal lobar degeneration | 1141 |
| Fuchs uveitis | 2176 |
| Functional bowel disorders | 70 |
| Functional disorders of the biliary tract | 592 |
| Functional dyspepsia | 2478 |
| Functional indigestion | 562 |
| Fungal infection | 39, 126, 177, 310, 402, 514, 707, 763, 795 |
| Fungal peritonitis | 39 |
| Furuncles | 287 |
| G | |
| Galactorrhea | 434 |
| Gallbladder bile sampling | 687 |
| Gallbladder cancer | 1009, 1226, 1286, 1920, 2369 |
| Gallbladder stone disease | 145, 1920 |
| Gallbladder stone dissolution | 778 |
| Gallstone disease | 2487 |
| Gallstone formation | 1920 |
| Gardner’s syndrome | 1114 |
| Gardnerella vaginalis | 743 |
| Gastric adenocarcinoma | 237 |
| Gastric antacids | 1469 |
| Gastric cancer | 247, 870, 937, 968, 1009, 1095, 1114, 1240, 1316, 1341, 1484, 1602, 2025, 2090, 2105, 2109, 2219, 2270, 2275, 2287, 2297, 2307, 2369, 2412, 2422, 2480, 2518, 2526, 2528 |
| Gastric cancer and Helicobacter pylori | 2192, 2197 |
| Gastric cardiac adenocarcinoma | 2445, 2526 |
| Gastric expression | 1484 |
| Gastric hyperacidity | 691 |
| Gastric hypersecretory states | 160, 640 |
| Gastric tumors | 1747 |
| Gastric ulcer | 160, 279, 494, 534, 545, 645 |
| Gastrinoma | 539, 678 |
| Gastroenteritis | 276 |
| Gastroesophageal reflux diseases | 160, 163, 215, 279, 296, 415, 481, 534, 545, 564, 640, 645, 1414, 2197 |
| Gastrointestinal cancer | 1602 |
| Gastrointestinal complications | 160 |
| Gastrointestinal diseases | 613, 763 |
| Gastrointestinal hypersecretory disorders | 640 |
| Gastrointestinal infections | 140 |
| Gastrointestinal prokinetics | 1748 |
| Gastrointestinal side-effects | 1483 |
| Gastrointestinal stromal tumor | 376, 712, 2238, 2331 |
| Gastrointestinal tract | 66 |
| Gastroparesis | 163 |
| Gastroschisis | 2434 |
| GATA4 deficiency | 1962 |
| Gaucher’s disease | 1032 |
| Gaucher’s disease (type 1) | 20, 377, 490 |
| Gender | 872, 1469, 1921 |
| Gender-related differences | 1316, 1485, 1962 |
| Gene interactions | 1141 |
| Gene silencing | 1142 |
| General anesthesia | 397, 472, 487, 496, 563, 593, 622, 624, 646, 648, 663, 682, 705, 706, 734, 786 |
| Generalized aggressive periodontitis | 2197 |
| Generalized anxiety disorder | 567, 787, 1447 |
| Generalized epilepsy with febrile seizures plus 2 | 2386 |
| Generalized epilepsy with febrile seizures plus, type 7 | 2390 |
| Generalized tonic-clonic seizures (grand mal) | 118, 617 |
| Generalized tonic-clonic (grand mal), complex partial seizures | 617 |
| Genetic markers for antidepressant medication intolerance | 1535 |
| Genetic predictors of inter-individual variability | 1748 |
| Genetic variation in the human AS3MT gene | 1191 |
| Genital and perianal warts | 379, 687 |
| Genital herpes | 10, 779 |
| Genital infections | 129 |
| Genital warts | 359, 388, 600 |
| Genitourinary irrigant | 698 |
| Genitourinary tract infections | 140, 536 |
| Genomic index of sensitivity to endocrine therapy | 1962 |
| Genomic instability | 1010 |
| Germ cell tumor | 88, 2238 |
| Germline genetic variation | 1485 |
| Gerstmann-Sträussler disease | 2349 |
| Gestational diabetes mellitus | 1962, 2149, 2190, 2235 |
| Gestational hypertension | 1938 |
| Gestational trophoblastic neoplasm | 198 |
| GGN repeat polymorphisms | 1185 |
| GH stimulation | 680 |
| Ghosal hematodiaphyseal dysplasia syndrome | 2440 |
| GI hemorrhage | 785 |
| Giardiasis | 743 |
| Gilbert’s syndrome | 2487, 2494, 2496, 2499 |
| Gingival hyperplasia | 1749 |
| Gingivitis | 119, 255 |
| Gitelman syndrome | 2402 |
| Glanzmann thrombasthenia | 2226 |
| Glaucoma | 8, 117, 166, 590, 742, 1077, 1090, 1142, 2287 |
| Glaucoma surgery | 624 |
| Glioblastoma | 937, 1010, 1235, 1240, 1750, 2025, 2115, 2120, 2203, 2270, 2271, 2333, 2471 |
| Glioblastoma multiforme | 124, 721, 1002, 2343 |
| Glioma | 872, 978, 1002, 1010, 1045, 1231, 1962, 2441 |
| Glucocorticoid receptor | 1750 |
| Glucocorticoid resistance | 2316 |
| Glucocorticoid-induced hypertension | 2249 |
| Glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia | 1750 |
| Glucocorticoid-induced osteoporosis | 18, 657 |
| Glucocorticoid-remediable aldosteronism | 1938 |
| Glucose homeostasis | 2343 |
| Glucose metabolism | 2052 |
| Glucose-6-phosphate dehydrogenase deficiency | 2077 |
| Glucosylceramide synthase | 872 |
| Glucuronic acid epimerase | 1142 |
| Glucuronidation | 1750 |
| Glutathione synthetase deficiency | 2103 |
| Glutathione synthetase deficiency of erythrocytes | 2103 |
| Glutathione transferases (GSTs) superfamily | 2107 |
| Gonadal ontogeny | 1962 |
| Gonorrhea | 134, 137, 138, 536, 540, 574, 700, 731 |
| Goose fatty liver | 1921 |
| Gout | 53, 572, 2259, 2445 |
| Gouty arthritis | 21, 617, 709, 764 |
| GP88 (PC-Cell derived growth factor, Progranulin) | 1962 |
| gp120 binding B40 aptamer | 1751 |
| Graft vs host disease | 732, 795, 2143 |
| Gram-negative bacterial infection | 29, 63, 183, 377, 731, 740, 747, 748, 2452 |
| Gram-negative organisms | 731, 747 |
| Gram-positive organisms | 65, 377, 731 |
| Grand mal | 617 |
| Granulocytic leukemia | 734 |
| Granuloma annulare lesions | 764 |
| Graves disease, susceptibility to | 1077, 2090 |
| Graves’ disease | 1077, 1274, 1991, 2090, 2130, 2176, 2203, 2207, 2224, 2287 |
| Graves’ ophthalmopathy | 991 |
| Graves-Basedow disease | 873 |
| GRF test | 680 |
| Group X secretory phospholipase A2 | 818, 992 |
| Growth failure | 697 |
| Growth hormone | 1486 |
| Growth hormone deficiency | 175, 697 |
| Growth hormone secreting pituitary tumors | 2090 |
| Guanosine triphosphate | 1010, 2154 |
| Guillain-Barré syndrome | 1142, 2058 |
| Guillain-Barré syndrome and experimental autoimmune neuritis | 1142 |
| Gut microbes | 874 |
| Gynecologic cancers | 1983 |
| Gynecologic infections | 132, 133, 137, 377, 740 |
| H | |
| Haemophilus influenzae type b infection | 39, 63, 134, 337, 353, 654, 2215 |
| Hair and skin pigmentation | 2267 |
| Hair growth | 1963 |
| Hairy cell leukemia | 167, 386, 387,578 |
| Haloperidol pyridinium neurotoxicity | 1488 |
| Hand dermatoses | 613 |
| Hand-foot syndrome | 1243 |
| HAP1 (Huntingtin-associated protein 1)(17q21.2-q21.3) | 2173 |
| HAPIP (Huntingtin-associated protein-interacting protein) | 2173 |
| Haptoglobin | 1142 |
| Hashimoto’s thyroiditis | 1274, 2439 |
| Hay fever | 304 |
| HBV infection | 1755 |
| HDL (reconsitituted) | 1142 |
| HDL-Cholesterol | 818, 824, 1161, 1244, 2037, 2044, 2338, 2385, 2460 |
| HDL cholesteryl ester | 2385 |
| Head and neck cancer | 28, 316, 792, 1010, 1056, 1286, 1415, 1619, 2294, 2471, 2488, 2499 |
| Head and neck squamous cell carcinoma | 1317, 1341, 1389, 1602, 2291, 2307, 2380, 2412, 2442, 2445 |
| Head lice | 449 |
| Headache | 144, 228, 342, 1755 |
| Hearing disorders | 791 |
| Heart | 1010 |
| Heart CYP expression | 1619 |
| Heart failure | 79, 86, 114, 117, 125, 153, 158, 261, 355, 433, 491, 636, 754, 758, 782, 1071,1939, 2098, 2228 |
| Heart transplant | 714, 780, 874 |
| Heart, kidney, or liver transplant recipients | 713 |
| Heartburn | 296 |
| Heat shock proteins (HSP60, HSP72, HSP90, and HSC70) | 1010 |
| Heavy metal detoxification | 937 |
| Hedgehog signaling | 874 |
| Heinz body anemias | 2125 |
| Helicobacter pylori infection | 38, 86, 415, 545, 640, 645, 731, 1415, 1416, 1756, 2199, 2343 |
| Helicobacter pylori-related chronic gastritis/gastric ulcer | 415, 874 |
| Helminthic infections | 733 |
| Hematologic diseases | 613, 764 |
| Hematologic malignant diseases | 1619 |
| Hematopoietic stem cell proliferation | 819 |
| Hematopoietic stem cell transplantation | 2287 |
| Heme | 1010, 1182, 2054, 2446 |
| Heme oxygenase-1 | 1317, 1603 |
| Hemiballismus | 729 |
| Hemodialysis | 682, 1756 |
| Hemoglobinopathies | 2125 |
| Hemolytic anemia due to glutathione synthetase deficiency | 2103 |
| Hemolytic-uremic syndrome | 1245 |
| Hemophilia | 295, 759 |
| Hemophilia A | 43, 44, 211, 295 |
| Hemophilia B | 43, 295 |
| Hemorrhage | 266 |
| Hemorrhagic shock | 1389, 1489 |
| Hemorrhoids | 73, 221, 255, 610, 798 |
| Hemostasis | 183, 737 |
| Heparin overdosage | 627 |
| Heparin-induced thrombocytopenia | 48 |
| Hepatic cirrhosis | 29, 285, 333 |
| Hepatic coma | 566 |
| Hepatic drug transport | 2409 |
| Hepatic encephalopathy | 519 |
| Hepatic ischemia-reperfusion injury | 1603 |
| Hepatic lipase deficiency | 2250 |
| Hepatic steatosis | 675, 1756, 1787 |
| Hepatic steatosis and acetaminophen hepatotoxicity | 1469 |
| Hepatic venocclusive disease | 2105 |
| Hepatitis | 1603, 1756 |
| Hepatitis A | 357, 379 |
| Hepatitis B | 387, 1142, 1226, 2138, 2143 |
| Hepatitis B and hepatocellular carcinoma | 2215 |
| Hepatitis B infection | 2037 |
| Hepatitis C | 386, 387, 388, 1142, 1226, 1489, 2143, 2179, 2182 |
| Hepatitis C virus protease inhibitor S5 | 874 |
| Hepatoblastoma | 874, 937, 1114 |
| Hepatocarcinoma | 874 |
| Hepatocellular carcinoma | 929, 1011, 1114, 1218, 1267, 1317, 1603, 1908, 1921, 2037, 2115, 2144, 2369, 2471, 2499 |
| Hepatocellular carcinoma (childhood type) | 2270 |
| Hepatocellular tumors | 1756, 2240 |
| Hepatocyte growth factor | 1363, 1756 |
| Hepatocyte nuclear factor 1 alpha | 1922 |
| Hepatocyte nuclear factor 3 gamma | 1403 |
| Hepatocyte nuclear factor 4 alpha | 1373, 1757 |
| Hepatocyte transplantation | 875, 1603 |
| Hepato-intestinal metabolic activity | 1489 |
| Hepatoma cell line H4IIE | 1287 |
| Hepatoma cells | 1757 |
| Hepatoma multidrug resistant cell line SK-Hep-1 | 937 |
| Hepatotoxicity | 1489, 1569, 2294 |
| Hepatotrophic factor | 1757 |
| Herbal bioactivation | 1287 |
| Hereditary angioedema | 200, 254 |
| Hereditary antithrombin III deficiency | 44 |
| Hereditary hemochromatosis | 2128 |
| Hereditary hemorrhagic telangiectasia 2 | 1047 |
| Hereditary hypertriglyceridemia | 1922 |
| Hereditary nonpolyposis colorectal cancer, type 2 | 2273 |
| Hereditary nonpolyposis colorectal neoplasms | 2279 |
| Hereditary sensory and autonomic neuropathy (type II) | 2522 |
| Hereditary spastic paraplegia type 5 | 1922 |
| Hereditary spastic paresis | 1922, 1984 |
| Hereditary tyrosinemia type 1 | 530 |
| Hermansky-Pudlak syndrome 7 | 2009 |
| Herpes genitalis | 10, 296, 779 |
| Herpes simplex encephalitis | 10 |
| Herpes simplex infection | 10, 237, 296, 411 |
| Herpes simplex labialis | 10, 255, 296, 411, 573, 779 |
| Herpes simplex virus types 1 and 2 | 767 |
| Herpes zoster | 10, 296, 779, 810 |
| Hertwig’s epithelial root sheath/Epithelial rests of Malassez cells | 1011 |
| Heterotopic ossification | 287 |
| Heterozygous familial hypercholesterolemia | 299, 611, 686 |
| Hiccups | 152 |
| High blood pressure | 791 |
| High density lipoprotein cholesterol | 992, 1143, 1363, 2012, 2249 |
| High density lipoprotein deficiency type 1 | 813, 1115, 1116 |
| High density lipoprotein deficiency type 2 | 813, 1115, 1116 |
| High-fat diet | 1317, 1603 |
| High-grade malignant glioma | 124 |
| High-mobility group box protein 1 | 1143 |
| High-throughput analysis of drug-drug interactions | 1760 |
| High-throughput genotyping method | 1493 |
| High-throughput single nucleotide polymorphism screening | 1317 |
| HIP1 (Huntingtin-interacting protein 1) | 2173 |
| HIP2 (Huntingtin-interacting protein 2) | 2173 |
| HIP12 (Huntingtin-interacting protein 12) | 2173 |
| HIP14 (Huntingtin-interacting protein 14) | 2173 |
| Hippocampal neurogenesis | 1963 |
| Hippocampal sclerosis | 1143 |
| Hippocampal volume | 1143 |
| Hirschsprung’s disease | 2379 |
| Hirsutism | 259, 701 |
| Histamine | 1143 |
| Histamine pharmacogenetics | 2155 |
| Histiocytosis | 791 |
| Histone demethylase LSD1 deficiency | 1939 |
| Histone methylation | 1760 |
| Histone methyltransferase G9a | 1922 |
| Histoplasma capsulatum | 39 |
| Histoplasmosis | 310, 402, 407, 1760 |
| HIV infection | 1, 2, 40, 55, 58, 224, 328, 382, 413, 451, 518, 653, 659, 660, 674, 702, 723, 801, 804, 813, 819, 875, 965, 1121, 1143, 1223, 1226, 1318, 1760, 1984, 1992, 1993, 2055, 2056, 2126, 2131, 2135, 2152, 2181, 2199, 2214, 2315, 2451 |
| HIV-1 infection | 203, 207, 258, 261, 262, 291, 328, 642, 745, 2452 |
| HIV-1 mother-to-child transmission | 1227 |
| Hodgkin Reed-Sternberg cells | 938 |
| Hodgkin’s and non-Hodgkin lymphoma | 146, 190, 195, 619, 791, 792 |
| Hodgkin’s disease | 124, 196, 436, 454, 619, 703, 791 |
| Hodgkin’s lymphoma | 88, 619, 792, 1761 |
| Homocysteine | 1040, 1171, 1182, 1196, 1216, 2013, 2086, 2288, 2291, 2300, 2425, 2513, 2519 |
| Homocystinuria | 78, 1220, 2287 |
| Homology modeling | 876 |
| Homophily and heterophily | 1353 |
| Homotropic/Heterotropic cooperativity | 1759, 1761 |
| Homozygous cystinuria | 745 |
| Homozygous familial hypercholesterolemia | 294, 686 |
| Homozygous sitosterolemia | 294 |
| Hookworms | 453 |
| Hormonal imbalance | 281 |
| Hormone refractory prostate cancer | 106, 1963 |
| Hormone replacement therapy | 819, 876, 1318, 1762, 2250 |
| Hormone-dependent advanced prostate cancer | 101 |
| Hot flushes | 273, 787, 2042 |
| Human influenza | 2214 |
| Human kinetic adjustment factor | 1318 |
| Humectant | 698 |
| Humerospinal dysostosis | 1257 |
| Huntingtin (HTT) | 2172 |
| Huntingtin-associated proteins | 2173 |
| Huntington’s chorea | 729 |
| Huntington’s disease | 710, 1061, 2096, 2173 |
| Huntington’s disease-like 1 | 2350 |
| Hurler and Hurler-Scheie forms | 417 |
| Hyaline membrane disease | 76 |
| Hydronephrosis | 1287 |
| Hydroxycholesterols | 1932 |
| Hyperacidity | 26, 447 |
| Hyperactive children | 152 |
| Hyperalphalipoproteinemia | 1244 |
| Hyperammonemia | 123 |
| Hyperandrogenic states in pregnancy | 1963 |
| Hyperandrogenism | 2207, 2466 |
| Hyperapobetalipoproteinemia | 2052, 2339 |
| Hyperbilirrubinemia | 1922, 2416, 2488 |
| Hypercalcemia | 108, 171, 335, 562, 806 |
| Hypercholanemia | 2021 |
| Hypercholesterolemia | 155, 294, 299, 323, 442, 522, 611, 618, 667, 686, 1923, 2146, 2253, 2306 |
| Hypercholesterolemia, familial | 686 |
| Hypercoagulability disorder | 2521 |
| Hyperemia | 1049 |
| Hyperglycemia | 514, 1993 |
| Hyperglycemia-induced liver injury | 1603 |
| Hyperhidrosis | 368 |
| Hyperhomocysteinemia | 78, 1220, 1619, 2287, 2291, 2297 |
| Hyperinsulinemia | 1027 |
| Hyperkalemia | 111, 112, 691, 695 |
| Hyperkalemic periodic paralysis | 2388 |
| Hyperkinetic movement disorders | 729 |
| Hyperlipidemia | 82, 597, 611, 667, 686, 819, 1120, 1144, 2253 |
| Hyperlipidemia type IIB | 992 |
| Hyperlipoproteinemia | 611 |
| Hyperlipoproteinemia (type I) | 611 |
| Hyperlipoproteinemia (type Ib) | 611 |
| Hyperlipoproteinemia (type II) | 611 |
| Hyperlipoproteinemia (type IIA) | 611 |
| Hyperlipoproteinemia (type III) | 611 |
| Hyperlipoproteinemia (type V) | 611, 1117 |
| Hypermagnesemia | 111 |
| Hyperosmotic laxative | 698 |
| Hyperoxic lung injury | 1287 |
| Hyperparathyroidism | 2268 |
| Hyperparathyroidism (secondary) | 246 |
| Hyperphosphatemia | 26, 110, 111 |
| Hyperpigmentation | 365 |
| Hyperprolactinemia | 94, 106, 635, 1549 |
| Hyperprothrombinemia | 2048 |
| Hypersensitivity | 2154 |
| Hypersensitivity pneumonitis | 2438 |
| Hypertension | 5, 21, 29, 34, 56, 70, 86, 98, 117, 125, 150, 153, 158, 175, 221, 244, 261, 268, 270, 298, 300, 331, 351, 352, 355, 361, 362, 381, 394, 401, 411, 412, 433, 441, 453, 476, 481, 482, 492, 498, 507, 515, 523, 525, 528, 542, 553, 581, 586, 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 992, 1032, 1051, 1063, 1066, 1068, 1071, 1077, 1081, 1086, 1090, 1095, 1105, 1144, 1197, 1214, 1318, 1341, 1373, 1415, 1469, 1496, 1619, 1762, 1908, 1923, 1936, 1939, 2044, 2060, 2105, 2226, 2287, 2292, 2346, 2365, 2391, 2403, 2410, 2424, 2522, 2525 |
| Hypertension resistant to conventional therapy | 2299 |
| Hypertension secondary to pre-eclampsia/eclampsia | 361 |
| Hypertension, essential | 114, 229, 1035, 1933, 2006, 2023, 2093, 2143, 2380, 2415 |
| Hypertensive crisis | 279 |
| Hyperthyroidism | 471, 627, 692 |
| Hypertriglyceridemia | 82, 299, 339, 522, 544, 782, 1044, 1116, 1117, 1144, 2052, 2253, 2306 |
| Hypertrophic cardiomyopathy | 1036, 1939, 2281, 2346 |
| Hypertrophic obstructive cardiomyopathy | 626 |
| Hypertrophic subaortic stenosis | 626 |
| Hyperuricemia | 21, 297, 617 |
| Hypervitaminosis D | 1984 |
| Hypnosedatives | 780, 1495 |
| Hypoaldosteronism | 29 |
| Hypocalcemia | 109, 111, 112 |
| Hypocalcemic tetany | 111, 229 |
| Hypochloremia | 691 |
| Hypochloremic states | 35 |
| Hypochlorhydria | 78 |
| Hypocitraturia | 606 |
| Hypodermoclysis | 360 |
| Hypoestrogenism | 281 |
| Hypoglycemia | 346, 1993 |
| Hypogonadal osteoporosis | 727 |
| Hypogonadism | 479 |
| Hypogonadotropic hypogonadism | 156, 326 |
| Hypokalemia | 605, 606, 701 |
| Hypokalemic periodic paralysis | 222, 2388 |
| Hypomagnesemia | 445, 446, 449 |
| Hyponatremia | 690, 691, 754 |
| Hypoparathyroidism | 109, 110, 111, 272 |
| Hypophosphatemia | 272, 607, 694 |
| Hypoplastic left ventricle | 24 |
| Hypoprothrombinemia | 589 |
| Hyposalivation | 672 |
| Hypospadias | 1287 |
| Hypotension | 265, 355, 587 |
| Hypothalamic amenorrhea | 349 |
| Hypothalamic-pituitary ACTH function | 484 |
| Hypothermia | 1763 |
| Hypothyroidism | 428, 431, 737, 1923, 1991 |
| Hypoxemia | 556 |
| Hypoxia | 1495, 1763 |
| Hypoxia-induced extracellular acidosis | 877 |
| Hypoxia-inducible factor 1 | 1341 |
| Hypoxia-inducible factor-1alpha (HIF1A) | 877, 1011 |
| Hypoxic respiratory failure | 531 |
| I | |
| IC50-based approaches for assessment of time-dependent inhibition of CYP3A4 | 1763 |
| Ichthyosis | 1909 |
| Idiopathic arthritis | 284 |
| Idiopathic chronic urticaria | 254 |
| Idiopathic dilated cardiomyopathy | 2445 |
| Idiopathic edema | 285 |
| Idiopathic hirsutism | 1963 |
| Idiopathic hypereosinophilic syndrome | 2329, 2331 |
| Idiopathic male infertility | 1341, 2287, 2299 |
| Idiopathic Parkinson’s disease | 120, 609, 647, 665, 668, 751 |
| Idiopathic pulmonary arterial hypertension | 269, 375, 762, 1047 |
| Idiopathic pulmonary fibrosis | 2442 |
| Idiopathic pulmonary hemosiderosis | 190 |
| Idiopathic recurrent miscarriages | 2430 |
| Idiopathic short stature | 697 |
| Idiopathic thrombocytopenia | 665, 2226 |
| Idiopathic thrombocytopenia purpura | 190, 260, 380, 651, 665 |
| Idiopathic uveitis | 146, 764 |
| Ifosfamide-induced hemorrhagic cystitis | 467 |
| IgA deficiency | 2144 |
| IgA nephropathy | 1032, 1087, 1939, 2193, 2328, 2343 |
| IL1B monoclonal antibodies | 1145 |
| Ileal resection | 1923 |
| Illicit growth promoters in cattle | 1963 |
| Immortalized non-tumorigenic human liver epithelial cells | 1766 |
| Immune function | 938 |
| Immunization against typhoid fever caused by Salmonella typh | 776 |
| Immunization against vaccinia virus | 690 |
| Immunization against varicella | 785 |
| Immunization with aldehyde-modified fibronectin | 1144 |
| Immunoglobulin deficiency | 379 |
| Immunosuppressant | 78, 614 |
| Immunotherapy | 2350 |
| Immunotherapy in elderly transplant recipients | 1766 |
| Impaired glucose tolerance | 2249 |
| Impetigo | 309, 504, 650 |
| Impotence | 479, 800 |
| Impulsivity | 2259 |
| In vitro fertilization | 1964 |
| In vitro interaction cocktail assays | 1771 |
| In vitro systems for assessment of CYP3A4 induction | 1771 |
| Inactivating mutations in the GNAS gene | 2090 |
| Inactive chloasma | 365 |
| Inclusion body myositis | 1144 |
| Increased frequency of APOE-4 in AD and protective effect of APOE-2 | 1127 |
| Indigestion | 144 |
| Individual variation | 1603 |
| Inducers | 938 |
| Inducers and inhibitors | 1341 |
| Induction of labor at term | 558 |
| Induction of ovulation | 462 |
| Industrial carcinogens | 2109 |
| Infant birth size | 1095 |
| Infant botulism | 92 |
| Infant colic | 368 |
| Infantile hypertrophic cardiomyopathy | 2280 |
| Infantile parkinsonism-dystonia syndrome | 2396 |
| Infantile spasms | 186, 755, 790 |
| Infected dermatoses | 532 |
| Infected or noninfected wounds | 409 |
| Infection respiratory tract | 700 |
| Infections | 147, 248, 608, 1144 |
| Infections by gram-positive bacilli | 65 |
| Infections of the skin | 63 |
| Infections of the upper and lower respiratory tract | 138 |
| Infectious diarrhea | 162 |
| Infectious mononucleosis | 2130 |
| Infective endocarditis | 38, 39, 169, 201 |
| Infertility | 337, 2038, 2075 |
| Infertility in Etv5-/- female mice | 1963 |
| Inflammasome | 1144 |
| Inflammation | 16, 53, 76, 94, 119, 170, 171, 192, 214, 223, 226, 227, 255, 291, 307, 322, 363, 365, 409, 413, 416, 440, 441, 448, 520, 524, 570, 657, 812, 992, 2167 |
| Inflammatory bowel disease | 437, 631, 878, 1767, 1909, 1923, 2176, 2193, 2197, 2200, 2227, 2311, 2343, 2370, 2403, 2430, 2456, 2477 |
| Inflammatory bowel disease 5 | 2408 |
| Inflammatory conditions | 316, 359, 441, 448, 764, 2359, 2360, 2362 |
| Inflammatory dermatosis | 78, 314, 613, 764 |
| Inflammatory disease | 5, 63, 137, 169, 540, 371, 709, 938 |
| Inflammatory myopathy | 2058 |
| Inflammatory phase of xerosis | 78 |
| Influence of APOE-CYP2D6 interactions on Alzheimer’s disease therapeutics | 1128 |
| Influence of CYP2D6 genotypes on liver transaminase activity | 1442 |
| Influenza | 255, 385, 548, 656, 803, 2144 |
| Influenza vaccination | 1144 |
| Insect bites and stings | 73, 287 |
| Insomnia | 35, 96, 144, 249, 273, 280, 284, 320, 359, 437, 439, 530, 634, 643, 677, 720, 765, 780, 802, 808, 809 |
| Insufficient blood flow | 791 |
| Insulin resistance | 1058, 1081, 2054, 2384, 2427 |
| Insulin resistance, susceptibility to | 1081 |
| Insulin secretion | 878 |
| Insulin sensitivity | 2093, 2247, 2344, 2346 |
| Insulin-dependent diabetes mellitus | 610, 1274, 2207 |
| Insulin-like growth factor-1 | 1145, 1768, 1963 |
| Insulin-like growth factor-1 deficiency | 454, 2188 |
| Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors | 1768 |
| Insulinoma and pancreatic cancer | 2297 |
| Intensive care | 624 |
| Interactions of anti-cancer drugs | 879 |
| Interleukin 1 receptor antagonist deficiency | 2197 |
| Intermediate metabolizers | 1506 |
| Intermittent claudication | 159, 342, 579 |
| Interruption of aortic arch | 24 |
| Interstitial cystitis | 231, 578 |
| Intestinal amebiasis | 248, 391, 566, 743 |
| Intestinal CYP3A and regulation of detoxifying systems in the liver | 1768 |
| Intestinal CYPs | 1619 |
| Intestinal expression | 938 |
| Intestinal metabolism | 1768 |
| Intestinal metabolizing enzymes | 1363, 1984 |
| Intestinal metaplasia | 2307 |
| Intestinal tract | 820 |
| Intestinal transporters | 879 |
| Intimal hyperplasia | 2364 |
| Intra-abdominal and urinary tract infections | 137 |
| Intra-abdominal infections | 132, 133, 162, 242, 275, 377, 465, 483, 741 |
| Intracerebral hemorrhage | 1145 |
| Intracranial hemorrhage in brain arteriovenous malformations | 1047, 2207 |
| Intracranial hypertension | 734 |
| Intracranial pressure | 450, 734 |
| Intracranial volume and white matter lesions | 1145 |
| Intractable chronic pain | 803 |
| Intrahepatic cholestasis | 1923 |
| Intrahepatic cholestasis of pregnancy | 929 |
| Intraocular hypertension | 125, 418, 423, 612, 742, 761 |
| Intraocular pressure | 46, 423, 450 |
| Intratumoral aromatase deficiency | 1963 |
| Intrauterine growth | 2088 |
| Intrauterine growth retardation associated with precocious puberty and sertoli cell hyperplasia (Russell-Silver syndrome-like phenotype) | 1963 |
| Intronic polymorphisms | 1498 |
| Invasive aspergillosis | 795, 2452 |
| Invasive cervical cancer | 2136 |
| Invasive fungal infections | 795, 1416 |
| Invasive pneumococcal disease | 2197 |
| Ionizing radiation | 1923 |
| IQ | 1145 |
| Iridectomy | 9 |
| Iridocyclitis | 677, 773 |
| Iron deficiency anemia, susceptibility to | 396 |
| Iron deprivation | 879 |
| Iron-deficiency anemia | 302, 303, 396, 602 |
| Irrigating solution | 66 |
| Irritable bowel syndrome | 22, 70, 224, 368, 443, 592, 624, 718, 768, 1066, 2093, 2456, 2475 |
| Irritations | 805 |
| Ischemia | 2112 |
| Ischemia-reperfusion injury | 879, 1374, 1469 |
| Ischemic and hemorrhagic stroke | 1051 |
| Ischemic cerebrovascular disease | 1119, 1269, 1477 |
| Ischemic heart disease | 1269, 2292, 2299, 2424 |
| Ischemic stroke | 611, 1059, 1079, 2056, 2060, 2203, 2225, 2287, 2306, 2353, 2370, 2445 |
| Islet cell carcinoma | 196 |
| Isolated growth hormone deficiency | 2086 |
| Isolated growth hormone deficiency (type IA) | 2086 |
| Isolated growth hormone deficiency (type IB) | 2086 |
| Isolated growth hormone deficiency (type II) | 2086 |
| Ispinesib/docetaxel combination-induced myelosuppression | 1773 |
| Itching eyes | 75, 771 |
| Ivermectin-sensitive Border Collie | 880 |
| J | |
| Japanese encephalitis | 405 |
| Jervell and Lange-Nielsen syndrome 1 | 2235 |
| Jervell and Lange-Nielsen syndrome 2 | 2228 |
| Joint osteoarthritis | 2197 |
| Juvenile idiopathic arthritis | 3, 11, 288, 2200, 2215 |
| Juvenile onset cholestasis | 1923 |
| Juvenile rheumatoid arthritis | 73, 139, 223, 288, 371, 459, 512, 550, 752 |
| K | |
| KATP channels | 983 |
| Kaposi’s sarcoma | 198, 791, 2207 |
| Kawasaki disease | 380, 1227, 2134, 2215, 2476 |
| Kearns-Sayre syndrome | 2285 |
| Keloid | 764 |
| Keratinocytes | 1288 |
| Keratitis | 514, 773 |
| Keratoconjunctivitis sicca-associated ocular inflammation | 192 |
| Keratoplasty | 9 |
| Kidney angiomyolipoma | 2182 |
| Kidney diseases | 1091, 2048 |
| Kidney failure | 1087 |
| Kidney proximal tubular cells | 1776 |
| Kidney transplant rejection | 1274 |
| Kidney transplantation | 61, 714, 780, 881 |
| Klebsiella | 39, 128 |
| Klinefelter’s syndrome | 1185, 1964 |
| Kohonen maps | 1776 |
| Korsakoff’s syndrome | 733 |
| Kowarski syndrome | 2086 |
| Kuru | 2350 |
| L | |
| Lacrimation | 771 |
| Lactase deficiency | 2243 |
| Lactation | 1924 |
| Lactose intolerance | 412 |
| Lacunar infarcts | 1105 |
| Lambert-Eaton myasthenic syndrome | 28 |
| Lamellar ichthyosis type 3 | 1909 |
| Langerhans cell differentiation | 1013 |
| LAPTM4B | 882 |
| Large-joint osteoarthritis | 1964 |
| Laron syndrome | 2088 |
| Larsen’s syndrome | 1257 |
| Laryngeal carcinoma | 1013 |
| Laryngeal squamous cell carcinoma | 882, 1288, 1778 |
| Laryngospasm | 2388 |
| Larynx | 1904 |
| Larynx cancer | 1221 |
| Late-onset Alzheimer’s disease | 812, 1220, 2300 |
| LDL-cholesterol | 611, 2245, 2338 |
| Lead encephalopathy | 257 |
| Lead poisoning | 231, 257, 705, 1100 |
| Lead poisoning, susceptibility to | 257 |
| Leber’s hereditary optic neuropathy | 2280, 2281, 2282, 2283 |
| Lecithin cholesterol acyltransferase deficiency | 992 |
| Left ventricular dysfunction | 261 |
| Left ventricular dysfunction postmyocardial infarction | 117, 125, 758, 782 |
| Left ventricular failure | 502 |
| Left ventricular hypertrophy | 441, 1036, 1939, 2306 |
| Left ventricular hypervoltage | 1940 |
| Left ventricular mass | 2093 |
| Left ventricular systolic dysfunction | 2339 |
| Legionella pneumonia | 654 |
| Leigh’s syndrome | 2280, 2283 |
| Lennox-Gastaut syndrome | 297, 414, 669, 755 |
| Lentigo | 365 |
| Lepidoptera | 882 |
| Leprosy | 201, 2183, 2216, 2219, 2255, 2326 |
| Leptin receptor | 1146 |
| Leptospirosis | 1146, 2130 |
| Letrozole and Norethisterone acetate vs Letrozole and Triptorelin in endometriosis | 1965 |
| Letrozole, Misoprostol and Mifepristone in therapeutic abortion | 1965 |
| Letterer-Siwe disease | 791 |
| Leucine-induced hypoglycemia | 983 |
| Leukapheresis | 577 |
| Leukemia | 473, 791, 882, 964, 969, 978, 1363, 1778, 2307, 2240 |
| Leukemia, acute lymphocytic | 190, 195 |
| Leukopenia | 2314 |
| Leukotriene B4 receptor-1 | 1146 |
| Levodopa-induced dyskinesia | 1146 |
| Lewis lung carcinoma | 1013 |
| Lewy body dementia | 713, 2350, 2420 |
| Lichen planus plaques | 764 |
| Lichen simplex chronicus plaques | 764 |
| Liddle’s syndrome | 2391 |
| Life-threatening ventricular arrhythmias | 623, 748 |
| Li-Fraumeni syndrome | 2471 |
| Ligula intestinalis infection | 1965 |
| Lipid A | 2184, 2220, 2453 |
| Lipid abnormalities | 2207 |
| Lipid peroxides | 2106, 2111, 2121 |
| Lipids | 820, 883, 1242 |
| Lipid rafts | 820, 939 |
| Lipodystrophy | 1083, 2247, 2334, 2375 |
| Lipodystrophy induced by antiretroviral therapy in HIV patients | 1146 |
| Lipomatosis | 675 |
| Lipophilicity | 1502 |
| Lipoprotein glomerulopathy | 1146 |
| Lipoprotein lipase | 1146 |
| Lipoprotein lipase deficiency | 2253 |
| Lipoxygenase | 993 |
| Liquid chromatography-tandem mass spectrometry analysis | 1780 |
| Listeria infections | 39 |
| Lithocholic acid-induced liver injury | 1984 |
| Liver cancer | 883, 1604, 1781, 1940, 2110, 2295, 2297, 2518 |
| Liver cirrhosis | 1056, 2499 |
| Liver disease | 388, 1013, 1105, 1502, 1781 |
| Liver drug metabolism transcriptome | 1781 |
| Liver fatty acid binding protein | 1924 |
| Liver fibrosis | 883 |
| Liver receptor homolog-1 | 1924, 1965 |
| Liver regeneration | 1924 |
| Liver transplantation | 1416, 1503, 1781 |
| Liver X receptor | 1013, 1288 |
| Liver X receptor agonists | 820, 1781 |
| Liver X receptor alpha (LXRα) | 993 |
| Liver X receptor alpha/ NR1H3 | 1147 |
| Liver X receptor-activating ligands (DMHCA, TO901317) | 1146 |
| Local anesthesia | 99, 464, 616, 666, 730 |
| Loeys-Dietz syndrome | 2448 |
| Long QT syndrome | 1072, 2154, 2229, 2230, 2231, 2235, 2390 |
| Long QT syndrome-1 | 1072 |
| Long QT syndrome 1/2 | 2231, 2235 |
| Long QT syndrome 2 | 2231 |
| Long QT syndrome 2/3 | 2231 |
| Long QT syndrome 2/5 | 2231 |
| Long QT syndrome 2/9 | 2231 |
| Longevity | 1014, 1049, 1147, 1244, 1374, 1965 |
| Loss of transport function of SLC15A2 | 2404 |
| Low bone mineral content | 2249 |
| Low-density lipoproteins (LDL) | 820 |
| Low-density lipoprotein receptor-related protein 1b (LRP1b) | 993, 1147 |
| Lower respiratory tract disease | 561 |
| Lower respiratory tract infections | 63, 128, 137, 162, |
| Lower urinary tract | 1063 |
| Low-grade non-Hodgkin lymphoma | 757 |
| Lung adenocarcinoma | 2018, 2140, 2236, 2333 |
| Lung cancer | 190, 237, 274, 338, 436, 473, 619, 792, 884, 939, 969, 1014, 1056, 1254, 1288, 1320, 1342, 1353, 1504, 1604, 1784, 1904, 1965, 2018, 2021, 2025, 2033, 2110, 2116, 2120, 2130, 2134, 2144, 2240, 2242, 2295, 2297, 2308, 2319, 2337, 2362, 2370, 2379, 2404, 2405, 2442, 2450, 2471, 2515, 2526, 2528 |
| Lung cancer risk | 1254, 2055, 2337 |
| Lung cells | 1784 |
| Lung diseases | 2193 |
| Lung transcriptome | 1288 |
| Lupus | 2060 |
| Lupus erythematosus | 366, 1269, 2060, 2179, 2227 |
| Lupus nephritis | 190, 2183 |
| Luteinizing hormone | 1965 |
| Luteinizing hormone-releasing hormone agonists | 1965 |
| Lyme disease | 138 |
| Lymphatic metastasis in gastric carcinoma | 2331 |
| Lymphedema | 285, 1785 |
| Lymphoblastic leukemia | 2227 |
| Lymphocytes | 1619, 1785 |
| Lymphocytic leukemia | 247, 2471 |
| Lymphoid leucemia | 1237 |
| Lymphoma | 103, 473, 495, 736, 885, 1240 |
| Lymphoma, non-Hodgkin | 619, 757, 791 |
| Lymphoplasmacytic enteritis | 885 |
| Lymphoproliferative disorders | 2021 |
| Lynch syndrome | 1288 |
| LXR-Alpha | 954 |
| M | |
| Macrocytic anemia | 325 |
| Macroglobulinemia | 190 |
| Macrophage stimulatory lipopeptide 2 | 2372 |
| Macrophage lipid metabolism | 993 |
| Macrophages | 820, 885 |
| Macular degeneration | 790, 2158, 2253 |
| MAD2 | 885 |
| Madurella mycetomatis-induced mycetoma | 1965 |
| Maintenance of normal microflora in the gastrointestinal tract | 671 |
| Major depressive disorder | 14, 49, 100, 213, 252, 317, 567, 678, 681, 759, 787, 886, 1258, 1483, 2009, 2101, 2159, 2163, 2168, 2170, 2193, 2259, 2316, 2319, 2396, 2398, 2439, 2456, 2475, 2476 |
| Major PRNP variants associated with prion disease | 2350 |
| Malabsorption syndrome | 562 |
| Malaria | 36, 51, 149, 248, 255, 366, 458, 622, 633, 708, 886, 1320, 1786, 1990, 2056, 2078, 2134, 2153, 2176, 2219 |
| Male hypogonadism | 728 |
| Male infertility | 1096, 1186, 2335, 2526, 2528 |
| Malignant ascites | 127 |
| Malignant gliomas | 2329 |
| Malignant hypertension | 221 |
| Malignant hyperthermia | 200, 2382 |
| Malignant lymphomas | 247 |
| Malignant melanoma | 196, 387 |
| Malignant mesothelioma | 993, 1966 |
| Malignant murine skin tumors | 1966 |
| Malignant osteopetrosis | 390 |
| Malignant pleural effusion | 715 |
| Malignant pleural mesothelioma | 573 |
| Mammary tissue | 820 |
| Mandibular height | 2088 |
| Manganese deficiency | 449 |
| Manganese intoxication | 1504 |
| Mania | 152, 434 |
| Mantle cell lymphoma | 89, 1233 |
| Maroteaux-Lamy syndrome | 336 |
| Masculinization | 1966 |
| Mast cell leukemia | 2238 |
| Mastitis | 309 |
| Mastocytosis | 2238 |
| Maternal behavior | 1966 |
| Maternal depression effects on fetal neurodevelopment | 2398 |
| Maternal fine particulate matter exposure | 1504 |
| Maternal protein restriction-related epigenetic changes in offspring cholesterol | 1925 |
| Maternal tobacco use and risk of adverse pregnancy outcomes | 1353 |
| Maternal undernutrition | 1940 |
| Maternally transmitted diabetes mellitus-deafness syndrome | 2284 |
| Maturity-onset diabetes of the young | 1201 |
| Maturity-onset diabetes of the young type 1 (MODY1) | 2149 |
| McCune-Albright syndrome | 1966, 2090 |
| MDMA and designer drugs of the amphetamine type | 1478, 1555 |
| MDMA-induced neurotoxicity | 1479 |
| MDR1 RNAi | 886 |
| Measles (rubeola) | 379, 452, 453 |
| Mechanical ventilation | 663 |
| Mediterranean diet | 1147 |
| Medullary thyroid carcinoma | 196, 2379 |
| Medulloblastoma | 124 |
| Megaloblastic anemia | 325 |
| Melanoma | 17, 198, 367, 436, 619, 886, 939, 1231, 1240, 1984, 2027, 2031, 2211, 2238, 2267, 2331, 2515 |
| MELAS syndrome | 2282, 2283, 2285 |
| Melatonin and Silymarin in maneb- and paraquat-induced Parkinson’s disease phenotype | 1604 |
| Membranoproliferative glomerulonephritis | 1245 |
| Memory | 1147, 2163 |
| Memory deficits | 342, 791 |
| Memory disorder | 596 |
| Menarche | 1966 |
| Meniere’s disease | 77, 161 |
| Meningeal carcinomatosis | 1966 |
| Meningeal leukemia | 195 |
| Meningitis | 132, 137, 310 |
| Meningococcal disease | 39, 461, 2056 |
| Meningoencephalitic stage of Trypanosoma brucei gambiense infection | 259 |
| Menkes’ disease | 1193 |
| Menopausal neurosis | 702 |
| Menopause | 255, 281, 283, 1320, 1788, 2038 |
| Menstrual cycle | 1788, 2075 |
| Mental development | 1342 |
| Mental disorders | 1505, 1997, 2007 |
| Mental retardation | 1991 |
| Mental retardation X-linked type 63 (MRX63) | 1045 |
| MEOS (Microsomal Ethanol-Oxidizing System) | 1788 |
| Merkel cell carcinomas | 2329 |
| MERRF syndrome | 2284, 2285, 2335 |
| Mesothelioma | 887 |
| Meta-analysis of association studies investigating genes for PD | 1531 |
| Metabolic acidosis | 690, 691, 693, 772 |
| Metabolic alkalosis | 35 |
| Metabolic bone diseases | 2038 |
| Metabolic syndrome | 994, 1033, 1043, 1059, 1078, 1081, 1087, 1091, 1117, 1120, 1148, 1269, 1789, 1925, 1940, 1966, 2052, 2165, 2177, 2198, 2211, 2245, 2255, 2292, 2339, 2452 |
| Metabolic traits | 1148 |
| Metabolism of neurosteroids | 1479 |
| Metabolizing capacity | 1505 |
| Metastatic brain tumors | 124 |
| Metastatic breast cancer | 115, 274, 338, 416, 479, 511, 715, 728, 756 |
| Metastatic colorectal cancer | 81, 115, 143, 563, 2058 |
| Metastatic islet cell carcinoma of the pancreas | 704 |
| Metastatic ovarian carcinoma | 247, 367 |
| Metastatic prostate cancer | 83 |
| Metastatic tumors | 454 |
| Methanol or Ethylene glycol poisoning | 326 |
| Methotrexate toxicity | 421, 1049, 1191 |
| Methylation-related Tamoxifen resistance | 1508 |
| Methylcobalamin deficiency (cblG type) | 2291 |
| Methylenetetrahydrofolate reductase | 1925 |
| MGMT promoter methylation | 2271 |
| Microangiopathic ischemic stroke | 1269 |
| Microchimerism | 2456 |
| Microglia | 1148 |
| Micropenis | 2426 |
| MicroRNAs | 821, 994, 1015, 1793, 1925, 1967 |
| Microsporum infection | 725 |
| Middle ear infections | 556 |
| Migraine | 22, 90, 144, 255, 259, 313, 332, 480, 507, 513, 599, 662, 711, 742, 755, 780, 807, 1263, 1511, 1795, 1989, 2014, 2038, 2160, 2161, 2456, 2476 |
| Migraine with aura | 259, 313, 332, 662, 807, 1989, 2287 |
| Migraine without aura | 662, 807, 1989 |
| Mild cognitive impairment | 1148 |
| Mild-to-moderate metabolic acidosis | 690, 691, 693 |
| Mild-to-moderate pain | 180, 226, 371, 408, 448, 512, 457, 625, 673 |
| Milk cholesterol secretion | 994 |
| Milk fatty acids and traits | 1015 |
| Mineralocorticoid receptor activation | 1940 |
| Minor burns | 73, 610 |
| Miosis | 321 |
| miR-378 | 1604 |
| Mismatch repair cancer syndrome | 2273, 2279 |
| Mitochondrial CYP2E1 | 1605 |
| Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS) | 2282, 2283, 2285 |
| Mitochondrial neurogastrointestinal encephalopathy syndrome | 2335 |
| Mitochondrial permeability transition pore | 888 |
| Mitogen-activated protein kinases (MAPKs) | 1364, 1796 |
| Mixed dyslipidemia | 299, 675 |
| Mixed hyperlipidemia | 82, 294, 611, 667 |
| Moisturizer for dry, rough skin | 777 |
| Molecular interaction fields | 889 |
| Monoamine metabolite concentrations | 2167 |
| Monocyte locomotion inhibitory factor | 2185, 2195, 2201, 2209, 2217 |
| Monocytic leukocytes | 1619 |
| Mood disorders | 1050, 2001, 2399 |
| Moraxella catarrhalis | 63 |
| Morbid obesity | 2249, 2344 |
| Morbid obesity with hypogonadism | 2247 |
| Morganella morganii | 119 |
| Morphea | 607 |
| Motion sickness | 161, 189, 232, 455, 622, 677 |
| Mountain sickness | 1033, 1087, 1119 |
| Moyamoya disease | 2278 |
| Muckle-Wells syndrome | 113, 656 |
| Mucopolysaccharidosis I | 417 |
| Mucopolysaccharidosis VI | 336 |
| Mucosal-associated invariant T (MAIT) cells | 889 |
| Mucositis | 73, 672 |
| Muir-Torre syndrome | 2274, 2279 |
| Multidrug resistance gene HA117 | 889 |
| Multinodular goiter | 737 |
| Multiple endocrine adenomas | 296 |
| Multiple endocrine neoplasia, type I | 2268 |
| Multiple endocrine neoplasia, type II | 2379 |
| Multiple myeloma | 89, 124, 190, 460, 562, 599, 619, 732, 806, 890, 1342, 1417, 1799, 1990, 2211 |
| Multiple pterygium syndrome | 1252 |
| Multiple sclerosis | 190, 198, 200, 306, 389, 495, 514, 613, 889, 1149, 1227, 1274, 1984, 2131, 2139, 2144, 2183, 2193, 2198, 2200, 2255, 2267, 2270, 2344, 2361, 2445, 2465 |
| Multiple system atrophy | 2420 |
| Multixenobiotic transporters | 890 |
| Mumps | 452, 453 |
| Muscle paralysis | 609 |
| Muscle spasm | 123, 154, 189, 472, 677 |
| Muscle spasticity | 747 |
| Musculoskeletal pain | 154, 468, 772, 2163 |
| Mushroom poisoning | 632 |
| Myalgia in statin-treated patients | 2168 |
| Myasthenia gravis | 27, 186, 190, 257, 360, 519, 609, 632, 890, 1038, 1252 |
| Myasthenia gravis with thymus hyperplasia | 609 |
| Myasthenic syndrome | 2388 |
| Mycetoma (Madurella mycetomatis) | 1342 |
| Mycobacterial diseases | 285 |
| Mycobacterial infection | 406, 653, 704 |
| Mycobacterium tubercolosis infection | 2401 |
| Mycoplasma pneumoniae | 719 |
| Mycosis fungoides | 190, 454, 791 |
| Mydriasis | 59, 190, 773, 800 |
| Myeloblastic and lymphoid cell lines | 1799 |
| Myelodysplastic syndrome | 60, 205, 419, 795, 1046, 1271, 1799, 2120, 2128, 2285 |
| Myeloid reconstitution | 675 |
| Myeloid/lymphoid or mixed lineage leukemia | 2101 |
| Myelopoiesis | 1149 |
| Myocardial infarction (MI) | 53, 176, 327, 433, 502, 611, 626, 643, 703, 742, 1015, 1033, 1056, 1059, 1072, 1091, 1149, 1189, 1227, 1375, 1392, 1417, 1515, 1619, 1799, 1909, 1925, 2038, 2050, 2051, 2060, 2146, 2226, 2250, 2255, 2256, 2282, 2306, 2365, 2370, 2440, 2450, 2452 |
| Myocardial injury | 2226 |
| Myocardial ischemia | 565, 611, 626, 643, 703, 1087 |
| Myoclonic epilepsy associated with ragged-red fibers | 2284, 2285, 2335 |
| Myoclonic seizures | 174, 530 |
| Myoclonus | 1535 |
| Myofascial pain syndrome | 287 |
| Myoma | 1967 |
| Myoneural gastrointestinal encephalopathy syndrome | 2284 |
| Myophosphorylase deficiency | 1033 |
| Myosin regulatory light chain | 890 |
| Myositis | 234 |
| Myositis ossificans | 287 |
| Myxedema coma/precoma | 431 |
| N | |
| N-Acetyltransferases | 1322 |
| NAD | 1216, 2473 |
| NADP | 1295, 1346, 1368, 1400, 1423, 1613, 2352 |
| NADPH-CYP450 oxidoreductase | 1322, 1799 |
| N-Containing drugs and xenobiotics oxygenated by FMO1 | 2065 |
| N-Dealkylation | 1516 |
| Nano-biotechnology culture system | 1800 |
| Nanoparticles | 891, 1800 |
| Narcolepsy | 38, 49, 218, 478, 497, 693 |
| Narrow complex tachycardia | 618 |
| Narrow-angle glaucoma | 471 |
| Nasal and nasopharyngeal mucosal congestion | 799 |
| Nasal congestion | 255, 266, 512, 630, 731, 799 |
| Nasal delivery | 891 |
| Nasal mucosa | 1904 |
| Nasal polyps | 69, 97, 499 |
| Nasopharyngeal carcinoma | 940, 1015, 1605, 1620, 1801, 1904, 2131, 2153, 2275, 2471 |
| Nasopharyngeal mucosal congestion | 799 |
| Natural killer-cell neoplasms | 891 |
| Nausea/vomiting | 46, 144, 152, 161, 189, 230, 239, 249, 250, 329, 350, 546, 677, 1535, 2168 |
| Necrobiosis lipoidica diabeticorum | 764 |
| NEDD9 | 1149 |
| Neonatal alloimmune thrombocytopenia | 2225 |
| Neonatal diabetes mellitus | 2233 |
| Neonatal gastroesophageal reflux disease | 1417 |
| Neonatal severe hyperparathyroidism | 1212 |
| Neoplasm | 234, 613, 764, 1988, 1995, 2179, 2271, 2471, 2526 |
| Neovascular (wet) age-related macular degeneration | 644 |
| Nephritic syndrome | 362, 701 |
| Nephropathic cystinosis | 194 |
| Nephropathy | 21 |
| Nephrotic syndrome | 153, 190, 333, 381, 476, 764, 812, 892 |
| Nephrotoxicity | 1375, 2408 |
| Nephrotoxicity associated with cisplatin therapy | 695 |
| Neprilysin | 1149 |
| Nerve growth factor-mediated neurite outgrowth | 1150 |
| Nervous tension | 359 |
| Neural stem cell | 1150 |
| Neural tube defects | 325, 2288, 2291 |
| Neuralgia | 234, 334, 359, 702, 772 |
| Neuritic plaques | 1150 |
| Neuroblastoma | 164, 190, 196, 198, 247, 290, 400, 460, 755,791, 907, 940, 2190, 2207 |
| Neurocysticercosis | 14, 2453 |
| Neurodegenerative disorders | 141, 994, 2103, 2295 |
| Neurodermatitis | 78 |
| Neurofibrillary tangles | 2101 |
| Neurogenic bladder | 80, 368, 554 |
| Neurogenic bowel disturbances | 70 |
| Neuroinflammation | 1968 |
| Neuroleptic malignant syndrome | 1457, 1488, 1517, 1549 |
| Neuroleptic-related weight gain in schizophrenia | 1064 |
| Neurological toxicities | 632 |
| Neuromuscular blockade | 368 |
| Neuromyelitis optica | 1925 |
| Neuronal excitability and survival | 2071 |
| Neuropathic pain | 755, 787, 1803 |
| Neuropathy, ataxia, and retinitis pigmentosa | 2280 |
| Neuropsychiatric disorder and early-onset cataract | 2285 |
| Neurotic disorders | 37 |
| Neurotransmitters | 1803 |
| Neutralization of heparin during surgery or dialysis | 627 |
| Neutropenia | 305 |
| Neutropenic allogeneic hematopoietic stem cell recipients | 795 |
| Neutropenic fever | 795 |
| Neutrophil growth factors | 1392 |
| NF-kappaB | 894, 1803, 1808 |
| N-glycosylation of ABC transporters | 892 |
| NHERF-1 (Na+/H+ exchanger regulatory factor 1) | 956 |
| N-in-1 dosing pharmacokinetics | 1804 |
| Nicotine addiction | 1250, 1356, 1998, 2002, 2003 |
| Nicotine dependence | 2007, 2399 |
| Nicotine dependence, susceptibility to | 1997 |
| Nicotine replacement therapy | 2323 |
| Niemann-Pick C1 protein | 1925 |
| Niemann-Pick disease | 2304 |
| Niemann-Pick disease, type C | 821, 1150 |
| Niemann-Pick disease, type C1 | 2304 |
| Niemann-Pick disease, type D | 2304 |
| Nighttime sleep aid | 232 |
| Nitrous oxide sensitivity in MTHFR deficiency | 2288 |
| NK-Cell leukemia | 892 |
| Nocardiosis | 708, 709 |
| Nocturia | 307 |
| Nocturnal asthma | 328 |
| Nocturnal enuresis | 378 |
| Nocturnal frontal lobe epilepsy (type 1) | 1253 |
| Nodular acne | 400 |
| Noise-induced hearing loss | 2229 |
| Non-alcoholic fatty liver disease | 994, 1323, 1605, 1807, 2332, 2489 |
| Non-alcoholic steatohepatitis | 1605 |
| Non-articular rheumatism | 5 |
| Non-atopic asthma | 2203 |
| Non-coding vault RNAs | 1807 |
| Non-erosive reflux disease | 279 |
| Non-familial idiopathic cardiomyopathy | 2145, 2422 |
| Non-familial structural atrial fibrillation | 1940 |
| Non-familiar atrial fibrillation | 2231 |
| Non-fatal myocardial infarction and stroke | 2225 |
| Non-gonococcal urethritis | 276 |
| Non-growth hormone-deficient short stature | 697 |
| Non-Hodgkin lymphoma | 88, 124, 370, 436, 454, 599, 619, 757, 791, 792, 893, 1096, 1605, 2056, 2058, 2255, 2279, 2288 |
| Non-hypertrophic AK on face or scalp | 379 |
| Non-insulin-dependent diabetes mellitus | 344, 610, 649, 667, 689, 750, 751, 984, 2120, 2150, 2207, 2233, 2250 |
| Non-lymphocytic leukemias | 495 |
| Non-metastatic gestational trophoblastic disease | 231 |
| Non-myeloid malignancies | 269 |
| Non-obstructive urinary retention | 80 |
| Non-productive cough | 73 |
| Non-Q-wave myocardial infarction | 199, 271 |
| Non-small cell lung cancer | 338, 559, 573, 603, 723, 793, 893, 940, 964, 1016, 1240, 1342, 1375, 1807, 1968, 2018, 2029, 2031, 2193, 2224, 2528 |
| Non-spherocytic hemolytic anemia | 2078 |
| Non-squamous non-small cell lung cancer | 81 |
| Non-steroidal anti-inflammatory drug-associated gastrointestinal bleeding | 1393 |
| Non-ST-segment elevation | 176, 262, 263, 271, 531, 610, 637 |
| Non-syndromic sensorineural deafness | 2284 |
| Non-toxic goiter | 431 |
| Non-ulcer dyspepsia | 163 |
| Non-viral hepatitis-related hepatocellular carcinoma | 1968 |
| Noonan’s syndrome | 697, 1204, 2240, 2430 |
| Normal tension glaucoma | 2014 |
| Normal-pressure hydrocephalus | 1150 |
| NOS1 promoter repeat | 1150 |
| Nosocomial pneumonia | 162, 426, 430 |
| Novel substrates | 1808 |
| Nox1 NADPH oxidase | 1150 |
| Nrf2-dependent gene expression | 1151 |
| NSAID-associated gastric ulcer | 415 |
| NT5E deficiency (arterial calcification due to deficiency of CD73) | 978 |
| Nuclear factor (erythroid-derived 2)-like 2 | 1016 |
| Nuclear factor-erythroid 2 related factor 2 | 1354 |
| Nuclear receptors | 1808 |
| Nuclear receptors in oncology | 1808 |
| Nuclear transcription factors | 1809 |
| Nucleotides | 2227, 2324 |
| Nutrigenetics (gene-diet interaction) | 1151 |
| Nutritional disturbances | 699 |
| Nutritional factors | 1522 |
| Nutritional supplement | 188 |
| O | |
| Obesity | 225, 470, 547, 583, 586, 683, 821, 894, 994, 1059, 1059, 1067, 1072, 1078, 1081, 1088, 1151, 1203, 1269, 1323, 1926, 1968, 2001, 2079, 2093, 2107, 2170, 2207, 2243, 2249, 2253, 2292, 2304, 2306, 2337, 2346, 2427, 2483 |
| Obesity (severe) due to leptin deficiency | 2247 |
| Obesity and body mass index | 2342, 2344 |
| Obesity, hyperphagia, and developmental delay | 2320 |
| Obesity, susceptibility to | 1067, 1072, 1078, 1081, 1269, 2001 |
| Obesity-related fatty liver | 1926 |
| Obsessive-compulsive disorder | 173, 317, 324, 567, 681, 787, 1522, 2096, 2160, 2163, 2167, 2399 |
| Obsessive-compulsive disorder, susceptibility to | 2096 |
| Obstructive airway disease | 422, 673 |
| Obstructive sleep apnea syndrome | 49, 2014 |
| Occipital horn syndrome | 1193 |
| Occluded arteriovenous cannulas | 703 |
| Occult subfoveal choroidal neovascularization | 790 |
| Ocular aspergillosis | 39 |
| Ocular histoplasmosis | 790 |
| Ocular hypertension | 79, 84, 92, 93, 242, 418, 742, 761 |
| Ocular infections | 162, 768 |
| Ocular inflammation | 94, 192, 657, 764 |
| Ocular itching | 409, 543 |
| O-Glycosylation | 1151 |
| Oil sediment genotoxicity | 1940 |
| Oleoyl-Coenzyme A | 2106 |
| Oligoarticular juvenile idiopathic arthritis | 2140 |
| Oligodendroglioma | 1002 |
| Oliguria | 450 |
| Omani type spondylo-epiphyseal dysplasia | 1257 |
| Omeprazole-Amoxicillin dual therapy for Helicobacter pylori eradication | 1417 |
| Onchocerciasis | 403, 712, 2140 |
| One-and two-sided undescended testicles | 349 |
| Ontogenesis of CYP1A proteins | 1497 |
| Ontogeny | 1812 |
| Onychomycoses | 158, 402, 725, 1567, 1812 |
| Oocytes | 894 |
| Open-angle glaucoma | 84, 92, 93, 242, 256, 418, 423, 471, 480, 761, 1073, 1077, 2337 |
| Ophthalmic diseases | 613 |
| Ophthalmic epinephrine sensitivity reaction | 457 |
| Ophthalmic infections | 341, 748 |
| Opiate dependence | 99, 2323 |
| Opioid-related disorders | 510 |
| Opisthorchiasis | 14, 612 |
| Opisthorchis viverrini-associated cholangiocarcinoma | 1354, 1606 |
| Oral and laryngeal cancer | 1054 |
| Oral cancer | 1289, 1606, 2190 |
| Oral drug overdose | 393 |
| Oral lesions | 449, 764 |
| Oral mucositis | 253, 560 |
| Oral squamous cell carcinoma | 1016, 1342, 1606, 2289 |
| Oral ulcer | 449 |
| Organ transplantation | 895 |
| Organic anion-transporting polypeptides | 1926 |
| Organic solute transporter α deficiency | 1926 |
| Organophosphate poisoning, sensitivity to | 609 |
| Orofacial infections | 223, 700 |
| Orolaryngeal carcinoma | 2505 |
| Oronasopharyngeal itching | 771 |
| Oropharyngeal candidiasis | 177, 310, 603 |
| Oropharyngeal mucositis | 75 |
| Orphan nuclear receptors | 895 |
| Orthostatic hypotension | 265,488 |
| Orthostatic intolerance | 2395 |
| Osteitis deformans | 742 |
| Osteoarthritis | 53, 77, 116, 139, 155, 223, 226, 288, 291, 300, 307, 321, 383, 408, 440, 448, 459, 506, 512, 527, 550, 597, 704, 709, 724, 738, 752, 1186, 1991, 2198 |
| Osteoarthrosis | 5 |
| Osteogenesis imperfecta | 1261 |
| Osteogenic sarcoma | 247, 2375 |
| Osteolytic bone lesions | 562 |
| Osteomalacia | 110, 111, 1814 |
| Osteomyelitis | 76, 223, 309, 508, 549 |
| Osteonecrosis | 1375, 1814 |
| Osteopenia | 2207 |
| Osteoporosis | 18, 67, 108, 110, 111, 112, 113, 209, 281, 287, 370, 417, 550, 562, 641, 657, 727, 806, 1261, 1969, 2064, 2193, 2198, 2207, 2515 |
| Osteoporosis, postmenopausal | 209, 417, 641, 657, 727, 806 |
| Osteoporotic fracture risk | 2337 |
| Osteosarcoma | 473, 895, 1017, 1814, 2337, 2434, 2448, 2471 |
| Otitis externa | 214, 309, 465, 532, 540, 602 |
| Otitis media | 38, 63, 128, 129, 131, 134, 136, 137, 138, 140, 167, 540, 576, 600, 709, 768, 769 |
| Otosclerosis | 1261 |
| Ovarian cancer | 25, 81, 122, 146, 164, 190, 237, 247, 338, 386, 489, 549, 559, 755, 791, 793, 895, 940, 1017, 1053, 1083, 1207, 1209, 1233, 1235, 1237, 1240, 1272, 1289, 1375, 1393, 1620, 1814, 2025, 2075, 2113, 2151, 2226, 2240, 2326, 2333, 2370, 2382, 2442, 2471, 2515, 2519, 2526 |
| Ovarian dysgenesis | 2075 |
| Ovarian hyperstimulation syndrome | 1969, 2075 |
| Ovarian response to FSH | 2075 |
| Overactive bladder | 304, 696, 753, 774 |
| Overdose of anticholinesterase medications | 609 |
| Ovulation induction | 156, 325, 777 |
| Ovulatory failure | 172 |
| Oxidative stress | 1152, 1470, 1606, 1815 |
| Oxidized low-density lipoprotein | 1927 |
| Oxysterol | 994, 1152 |
| Oxysterol 7α-hydroxylase | 1927 |
| Oxysterol 27-hydroxycholesterol | 1984 |
| P | |
| P28GANK | 896 |
| p53 regulation | 2511 |
| P450cam | 1816 |
| Paclitaxel resistance | 2025 |
| Paclitaxel/Carboplatin-induced myelosuppression | 1375 |
| Paget disease of bone | 18, 108, 287, 562, 657, 742, 806 |
| Pain | 7, 53, 70, 75, 94, 99, 105, 116, 154, 155, 180, 200, 234, 255, 291, 300, 301, 362, 364, 408, 409, 440, 463, 469, 509, 520, 527, 557, 565, 577, 673, 717, 758, 772, 803, 1375, 2167, 2323, 2399, 2478 |
| Painful disorders | 5 |
| Palliative treatment of hyperthyroidism in preparation for surgical treatment or radioactive iodine | 627 |
| Palmar hyperhidrosis | 90 |
| Palpebral and bulbar conjunctivitis | 316, 613 |
| Pancreas | 1818 |
| Pancreatic cancer | 274, 338, 897, 964, 1017, 1207, 1240, 2179, 2180, 2188, 2213, 2240, 2268, 2428, 2471 |
| Pancreatic exocrine dysfunction | 678 |
| Pancreatic insufficiency | 456 |
| Pancreatitis | 368, 624, 1056 |
| Pancreatoduodenectomy | 1418 |
| Panic disorder | 23, 174, 317, 567, 681, 787, 1062, 1266, 2399 |
| Papillary thyroid carcinoma | 1114, 2393 |
| Papillary tumors | 68 |
| Paracoccidioidomycosis | 407 |
| Paralytic ileus | 217, 768 |
| Paramyotonia congenita of von Eulenburg | 2388 |
| Paraosteoarthropathy | 287 |
| Parathyroid adenoma | 2268 |
| Parathyroid carcinoma | 161 |
| Parathyroid tumors | 1212 |
| Parenteral nutrition | 694 |
| Parenteral nutrition solution | 220 |
| PARK genes | 1531 |
| Parkinson disease 8 | 2254 |
| Parkinson’s disease | 45, 72, 74, 94, 120, 166, 240, 335, 434, 609, 626, 647, 662, 665, 668, 678, 751, 767, 1056, 1062, 1152, 1264, 1264, 1324, 1343, 1529, 1819, 1969, 1989, 2001, 2003, 2005, 2078, 2081, 2098, 2112, 2113, 2116, 2128, 2193, 2254, 2260, 2264, 2283, 2288, 2291, 2295, 2308, 2326, 2337, 2420 |
| Parkinsonian syndrome | 70, 85, 94, 106, 232, 264, 580, 621, 1989 |
| Parkinsonism | 26, 120, 1981 |
| Parotid and submandibular glands | 940 |
| Paroxysmal atrial fibrillation | 618, 637 |
| Paroxysmal AV junctional rhythm | 637 |
| Paroxysmal extreme pain disorder | 2391 |
| Paroxysmal nocturnal hemoglobinuria | 256, 2242 |
| Paroxysmal supraventricular tachycardia | 12, 229, 618, 637 |
| Paroxysmal ventricular tachycardia | 235,637 |
| Partial or secondary generalized seizures | 79, 790 |
| Partial seizures | 118, 177, 287, 297, 334, 414, 552, 584, 588, 738, 781, 784, 808 |
| Patent ductus arteriosus | 383 |
| Pathologic myopia | 790 |
| Pathological hypersecretory conditions | 640, 645 |
| PCSK9 (Proprotein convertase subtilisin/kexin type 9) | 1152 |
| Pediatric acute nephritis | 449 |
| Pediatric solid tumors | 103 |
| Pediatric tuberculosis | 2402 |
| Pediculus humanus infestations | 582 |
| Pellagra | 522 |
| Pelvic infections | 275 |
| Pelvic inflammatory disease | 63, 137, 169 |
| Pemphigus | 60, 607 |
| Penicillin allergy | 2203, 2216 |
| Peptic ulcer | 70, 347, 368, 462, 475, 624, 2155 |
| Peptic ulcer (low dose aspirin-induced) | 1088 |
| Percutaneous coronary intervention | 610, 739 |
| Percutaneous transluminal coronary angioplasty | 746 |
| Perennial allergic rhinitis | 69, 97, 142, 151, 157, 168, 187, 193, 304, 584, 764, 771 |
| Periarthritis | 724 |
| Periarticular ossification | 287 |
| Periodontitis | 119, 162, 1153, 2213 |
| Perioperative blood loss, prevention | 47 |
| Perioperative genomic profiles | 1821 |
| Perioperative nausea and vomiting | 620 |
| Peripartum cardiomyopathy | 2358 |
| Peripheral and cerebral ischemia | 565 |
| Peripheral and pulmonary embolism | 797 |
| Peripheral arterial disease | 356, 2426 |
| Peripheral arterial occlusive disease | 2177 |
| Peripheral nervous system | 1153 |
| Peripheral neuropathy | 1274, 2341, 2422 |
| Peripheral stem cell transplantation | 675 |
| Peripheral vascular disease | 159, 355, 401, 522 |
| Peripheral vasospastic disorders | 751 |
| Peritonitis | 15, 310, 699 |
| Permanent neonatal diabetes mellitus | 984, 2233 |
| Pernicious anemia | 188 |
| Peroxisomal acyl-CoA oxidase deficiency | 1042 |
| Peroxisomal disorders | 1042 |
| Peroxisome proliferator | 2106, 2340 |
| Peroxisome proliferator-activated receptor alpha (PPARA) | 1393, 1620 |
| Peroxisome proliferator-activated receptor gamma1 (PPARG1) | 995 |
| Peroxisome proliferator activated receptor-gamma (PPARG)-coactivator 1alpha (PGC-1alpha) | 1471, 1927 |
| Peroxisome proliferator-activated receptor-gamma (PPARG), Pioglitazone and Rosiglitazone | 1941 |
| Peroxisome proliferator-activated receptor δ isosteric selenium agonists | 1153 |
| Perpetrators of pharmacokinetic drug-drug interactions | 1324 |
| Personality | 1537 |
| Personality disorders | 2005 |
| Personality traits | 2163, 2167 |
| Personality traits and substance dependence | 1053 |
| Pertussis | 255,276 |
| Peters’ anomaly | 1343 |
| Petit mal (absence) seizures | 475 |
| Petit mal epilepsy | 463 |
| Petit mal variant | 174 |
| Peyronie’s disease | 607 |
| P-Glycoprotein | 897, 898 |
| Pharmacodynamics | 1153 |
| Pharmacogenetic testing | 1393 |
| Pharmacokinetics in children | 1822 |
| Pharmacokinetics in the elderly | 1822 |
| Pharmacoresistant temporal lobe epilepsy | 899 |
| Pharyngitis/tonsillitis | 75, 128, 129, 130, 134, 136, 167 |
| Pharyngitis/tonsillitis due to Streptococcus pyogenes | 63 |
| Phase I and Phase II hepatic drug metabolism activities in human liver preparations | 1822 |
| Phenolic function | 1823 |
| Phenothiazine-induced bladder dysfunction | 80 |
| Phenotypic appearance and neuropathology findings from patients with the known PARK mutations | 1531 |
| Pheochromocytoma | 175, 484, 585, 586, 626, 2379 |
| Philadelphia chromosome-positive chronic myelogenous leukemia | 376, 386 |
| Phosphodiesterase type 5 (PDE5) | 1969 |
| Phospholipase D | 1909 |
| Phospholipids | 824, 1116, 1343, 1824, 2101 |
| Photodynamic therapy | 1017 |
| Physical activity/exercise | 1153 |
| Pick’s disease | 2264, 2357 |
| Piebaldism | 2238 |
| Pim-1 kinase | 1017 |
| Pinworm and roundworm infections | 453, 595, 631 |
| Pituitary adenoma | 2268 |
| Pituitary function test | 48, 628 |
| Pituitary TSH suppression | 428 |
| Pituitary-testicular function | 1969 |
| Pityriasis (tinea) versicolor | 104, 158, 256, 553 |
| Placenta | 822, 900, 995, 1018, 1290, 1343, 1826 |
| Placental abruption | 2300 |
| Plague | 704 |
| Plaque psoriasis | 11, 108, 109, 192, 315, 384, 718, 778 |
| Plasma apolipoprotein E | 1154 |
| Plasma concentrations | 1444 |
| Plasma volume expansion | 599 |
| Plasmodium chabaudi malaria | 1912, 1927 |
| Plasmodium falciparum malaria | 36, 51, 637, 1990 |
| Plasmodium ovale malaria | 616 |
| Plasmodium vivax malaria | 616 |
| Platelet activating factor | 824, 901, 1092, 1111, 1270, 2013, 2195, 2270, 2340, 2345, 2367, 2372, 2381, 2453, 2462 |
| Platelet aggregation | 2324, 2325 |
| Platinum-based chemotherapy | 2029 |
| Pleural mesothelioma | 1018 |
| Pneumococcal disease, invasive, protection against | 39 |
| Pneumoconiosis and occupationally related tumors | 1343 |
| Pneumocystis carinii pneumonia | 58, 576, 768 |
| Pneumocystis jiroveci (Pneumocystis carinii) pneumonia | 769, 770 |
| Pneumonia | 131, 223, 309, 310, 340, 600 |
| Poisoning | 145, 393 |
| Pokemon gene transcription | 901 |
| Polarized light irradiation | 1910 |
| Poliomyelitis | 601 |
| Polycystic ovary syndrome | 326, 1059, 1290, 1970, 2022, 2247, 2290, 2344 |
| Polydipsia | 211 |
| Polymicrobic infections | 377 |
| Polypoidal choroidal vasculopathy | 1245 |
| Polyuria | 211 |
| Pompe disease | 20 |
| Poor metabolizers | 1506 |
| Porphyria | 1827 |
| Porphyria cutanea tarda | 940, 1290, 1326 |
| Porphyria variegate | 2129 |
| Porphyrin metabolism | 1018 |
| Porphyromonas gingivalis | 1154 |
| Portal hypertension | 612 |
| Portal venous thrombosis | 797 |
| Portal-systemic encephalopathy | 413 |
| Postabortion hemorrhage | 273, 477, 558 |
| Post-encephalitic parkinsonism | 120, 677 |
| Posterolateral lumbar spinal fusion | 271 |
| Post-evacuation cholecystography | 687 |
| Post-herpetic neuralgia | 116, 615 |
| Post-menopausal endometriosis | 1970 |
| Post-menopausal hormone therapy | 1154 |
| Post-menopausal osteoporosis | 67, 110, 111, 112, 641, 657, 727, 806 |
| Post-menopausal urogenital symptoms | 281 |
| Post-myocardial infarction | 56, 79, 611, 742, 797 |
| Post-operative antiemetic | 622, 624 |
| Post-operative delirium | 1535 |
| Post-operative nausea and vomiting | 620, 768, 773 |
| Post-operative pain | 217, 424, 622, 666, 686, 724 |
| Post-operative trauma | 141 |
| Post-partum depression | 1264, 2259 |
| Post-partum hemorrhage | 122 |
| Post-stroke neurogenesis | 1970 |
| Post-surgical analgesia | 648 |
| Post-surgical and post-traumatic pain | 622, 666 |
| Post-surgical pain | 116, 622, 666, 686 |
| Post-traumatic epilepsy | 1154 |
| Post-traumatic stress disorder | 567, 2062 |
| Potassium deficiency | 604, 605 |
| Potential health risks of complementary alternative medicines in HIV patients | 1828 |
| PPARG agonist-induced edema and fluid retention | 2344 |
| Prader-Willi syndrome | 697 |
| Preanesthetic agent | 677 |
| Precocious puberty | 349, 358, 1829 |
| Precursor cell lymphoblastic leukemia-lymphoma | 1240, 2405 |
| Prediction of anticancer drug activity | 1343 |
| Prediction of oral drug interactions caused by CYP3A4 | 1829 |
| Pre-eclampsia | 449, 1088, 1970, 2012, 2022, 2038, 2050, 2288, 2445, 2453 |
| Pregnancy | 289, 1326, 1540, 1620, 1829, 1928 |
| Pregnancy loss | 489, 494 |
| Pregnancy-induced hypertension | 612, 2300 |
| Pregnane X nuclear receptor | 1395 |
| Pregnane X receptor | 902, 1154, 1830 |
| Premalignant genital lesions | 359 |
| Premature labor | 2120 |
| Premature ovarian failure | 1928, 1971, 2069 |
| Premature ventricular contractions | 618 |
| Premenstrual dysphoric disorder | 317, 567, 681 |
| Prenatal stress | 1971 |
| Preoperative medication | 677 |
| Preprolactin, glycoprotein alpha and luteinizing hormone beta gene expression | 1326 |
| Prepubertal cryptorchidism | 156 |
| Prepubertal gynecomastia in monozygotic twins with Peutz-Jeghers syndrome | 1971 |
| Preterm cardiorespiratory disease | 1033 |
| Prevention of cancer-chemotherapy-induced nausea and vomiting | 620, 773 |
| Prevention of kidney stone | 745 |
| Prevention of postoperative nausea and vomiting | 620, 768 |
| Prevention of pregnancy | 776 |
| Primary acute leukemia | 2179, 2180 |
| Primary aldosteronism | 1941 |
| Primary aldosteronism associated with subclinical Cushing’s syndrome | 1941 |
| Primary antiphospholipid syndrome | 1201 |
| Primary bile acid malabsorption | 2400 |
| Primary biliary cirrhosis | 778, 1540, 1832, 1928, 2145 |
| Primary brain tumors | 619, 903 |
| Primary central nervous system lymphoma | 903 |
| Primary congenital glaucoma | 1343 |
| Primary cultured human hepatocytes | 903 |
| Primary degenerative dementia | 342 |
| Primary dysmenorrhea | 139, 223, 408, 457, 527, 724 |
| Primary dystonia | 1154 |
| Primary erythermalgia | 2391 |
| Primary generalized tonic-clonic seizures | 423, 755 |
| Primary hyperaldosteronism | 701 |
| Primary hyperaldosteronism due to adrenal microadenoma | 1941 |
| Primary hypercholesterolemia | 182, 442, 618, 667, 686 |
| Primary hyperoxaluria (type I) | 1093 |
| Primary immunodeficiency syndromes | 380 |
| Primary insomnia | 2399 |
| Primary keratoconjunctivitis | 767 |
| Primary nephrotic syndrome | 2445 |
| Primary open-angle glaucoma | 1073, 1154, 1344, 2193 |
| Primary ovarian insufficiency | 1971 |
| Primary pulmonary hypertension | 361, 533, 612, 684, 1047, 1203, 1620 |
| Primary restless legs syndrome | 609, 665 |
| Primary spontaneous intracerebral hemorrhage | 1052 |
| Prion disease | 1154, 2350, 2351 |
| PRNP Met129Val polymorphism in Alzheimer’s disease and prion disorders | 2350 |
| Proatherogenic microbes | 1154 |
| Probe substrates for clinical drug interaction studies | 1832 |
| Procarcinogen activation | 1541 |
| Proctitis | 466, 1833 |
| Proctosigmoiditis | 466 |
| Progesterone deficiency | 621 |
| Progesterone receptor membrane component 1 (PGRMC1) | 1375 |
| Progressive external ophthalmoplegia | 2335 |
| Progressive external ophthalmoplegia with myoclonus | 2284 |
| Progressive external ophthalmoplegia, proximal myopathy, and sudden death | 2285 |
| Progressive familial intrahepatic cholestasis PFIC3 | 903 |
| Progressive osseous heteroplasia | 2091 |
| Progressive supranuclear palsy | 2264 |
| Prolactin-secreting adenomas | 94 |
| Proliferative diabetic retinopathy | 2177 |
| Proliferative vitreoretinopathy | 2255 |
| Prolonged bleeding time, brachydactyly and mental retardation | 2091 |
| Promotion of weight gain | 550 |
| Promoters for driving transgene expression | 1833 |
| Prophylaxis of acute organ rejection in renal transplant | 688 |
| Prostaglandin transporter | 1971 |
| Prostate cancer | 2, 101, 193, 207, 237, 281, 282, 321, 349, 358, 407, 422, 495, 526, 712, 772, 791, 822, 903, 970, 995, 1018, 1114, 1186, 1209, 1267, 1272, 1291, 1326, 1344, 1835, 1971, 1985, 2018, 2110, 2116, 2120, 2151, 2156, 2177, 2188, 2216, 2241, 2255, 2275, 2331, 2341, 2370, 2416, 2422, 2426, 2442, 2489, 2510, 2515, 2528 |
| Prostatic hyperplasia | 306, 1064, 1836 |
| Prostatitis | 140, 307, 426 |
| Protease inhibitor-associated hyperlipidemia | 1836 |
| Proteasome | 1607, 1836 |
| Protection against nicotine dependence | 2396 |
| Protein C deficiency | 2353 |
| Protein kinase Cβ (PKCβ) | 1928 |
| Proteomics of human blood-brain barrier transporters | 903 |
| Proteus infection | 29, 119, 128 |
| Pruritic dermatosis | 73,610,613 |
| Pruritus | 73, 155, 182, 188, 245, 368, 610 |
| Pruritus ani | 610, 798 |
| Pseudobulbar affect | 1545 |
| Pseudoexfoliation syndrome | 1142 |
| Pseudoexfoliative glaucoma | 2110, 2120 |
| Pseudohermaphroditism | 2317 |
| Pseudohypoaldosteronism | 1941 |
| Pseudohypoaldosteronism, type 1 | 2391 |
| Pseudohypoparathyroidism | 109 |
| Pseudohypoparathyroidism (type IA) | 2091 |
| Pseudohypoparathyroidism (type IB) | 2091 |
| Pseudomembranous colitis | 155, 783 |
| Pseudomonas aeruginosa infections | 29, 119, 131, 135, 594, 822 |
| Pseudopseudohypo-parathyroidism | 2091 |
| Pseudosymmetric solute translocation pathways | 904 |
| Pseudovaginal perineoscrotal hypospadias | 2426 |
| Pseudoxanthoma elasticum | 978, 2276 |
| Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency | 2083 |
| Psoriasis | 10, 42, 78, 179, 314, 473, 474, 672, 778, 940, 1155, 1228, 2126, 2136, 2216, 2220, 2456 |
| Psoriasis vulgaris | 255, 2220 |
| Psoriatic arthritis | 11, 60, 284, 348, 384, 2136, 2220, 2256, 2344 |
| Psoriatic plaques | 764 |
| Psychogeriatric patients | 1447 |
| Psychomotor and focal seizures | 617 |
| Psychosis | 95, 474, 580, 805, 810, 1155, 2399 |
| Psychosis/schizophrenia | 474, 620, 635, 658, 710, 735, 736, 766, 805, 810, 1064, 1067, 1250, 1255, 1264, 1998, 2001, 2004, 2006, 2007, 2009, 2079, 2094, 2096, 2097, 2099, 2231, 2323 |
| Psychostimulant abuse | 2323 |
| Psychotic depression | 37 |
| Psychotic disorders | 71, 319, 354, 442, 620, 736, 805, 2006 |
| Pterygium | 2528 |
| Puberty | 1838 |
| PUFA metabolism (Arachidonic acid, Eicosatrienoic acid, Eicosapentaenoic acid, Docosahexaenoic acid) | 1910 |
| Pulmonary alveolar proteinosis | 995 |
| Pulmonary arterial hypertension | 27, 90, 525, 612, 684, 689, 762, 1047, 1345, 2014, 2302 |
| Pulmonary artery pressure | 2328 |
| Pulmonary atresia | 24 |
| Pulmonary edema | 502 |
| Pulmonary embolism | 6, 218, 263, 327, 356, 703, 744, 777, 797, 2325 |
| Pulmonary emphysema | 745 |
| Pulmonary function | 310 |
| Pulmonary hypertension secondary to connective tissue disease | 689 |
| Pulmonary hypertension, familial persistent, of the newborn | 683 |
| Pulmonary stenosis | 24 |
| Pulmonary thromboembolism | 797 |
| Pulmonary tuberculosis | 191, 655, 2456 |
| Pulmonary vasoconstriction | 751 |
| Pulseless arrest | 785 |
| Puromycin aminonucleoside-induced nephrosis | 1980 |
| Purpura fulminans | 628 |
| Pyelonephritis | 131, 162, 275 |
| Pyodermas | 532 |
| Pyorrhea | 255 |
| Pyridoxine deficiency | 1607 |
| Pyridoxine-dependent seizures | 632 |
| Q | |
| QT dispersion (QTd) | 1033 |
| QT interval | 904, 1488, 1839 |
| R | |
| Rabies | 640, 641 |
| Radiation | 1155 |
| Radiation therapy | 1841 |
| Radiation therapy-induced mucositis | 672 |
| Radiation-induced apoptotic cell death | 905 |
| Radioiodine ablation of thyroid tissue remnants | 737 |
| Radiotracers | 905, 1019 |
| RANKL antibody | 1972 |
| Rasmussen’s encephalitis | 2094 |
| Rat strain differences | 1607 |
| Raynaud’s disease | 401, 612 |
| Reactive arthritis | 2402 |
| Receptor for activated C-kinase 1 (RACK1) | 1019 |
| Receptor for advanced glycation end products (RAGE) | 1155 |
| Recessive ataxia syndrome | 2335 |
| Rectal cancer | 316, 2528 |
| Recurrent cutaneous T-cell lymphoma | 608, 664, 796 |
| Recurrent miscarriage | 1291, 2061 |
| Reduce duodenal motility during diagnostic radiologic procedures | 624 |
| Reduced triglycerides, susceptibility to | 611 |
| Refractory acute lymphoblastic leukemia | 172 |
| Refractory acute myeloid leukemia | 2347 |
| Refractory constipation | 163 |
| Refractory cutaneous T-cell lymphoma | 82 |
| Refractory delirium tremens | 624 |
| Refractory depression | 100 |
| Refractory leukemia | 103 |
| Refractory non-Hodgkin lymphoma | 311, 608, 757 |
| Refractory rickets | 272 |
| Refractory testicular tumors | 290 |
| Regional analgesia | 464 |
| Regional anesthesia | 622 |
| Regulation of UGT1A1 by BRCA1 | 2489 |
| Relapsing-remitting multiple sclerosis | 343 |
| Relaxation of skeletal muscles | 646, 663, 705, 786 |
| Removal of granulation tissue and warts | 685 |
| Renal adenocarcinoma | 1910 |
| Renal agenesis | 2379 |
| Renal cancer | 17, 88, 292, 436, 456, 568, 698, 712, 722, 791, 941, 1274, 1345, 1420, 1843, 2270, 2297, 2337, 2385 |
| Renal colic | 5 |
| Renal CYP3A activity | 1843 |
| Renal damage | 1155 |
| Renal disease | 285, 2052 |
| Renal dysfunction | 699 |
| Renal failure in IgA nephropathy | 1088 |
| Renal function | 906 |
| Renal hypouricemia | 970 |
| Renal insufficiency | 111, 511 |
| Renal ischemia-reperfusion | 1607 |
| Renal transplantation | 67, 906, 1843 |
| Renal tubular dysgenesis | 1034, 1092, 2377 |
| Resistance to platinating agents | 1193 |
| Resistant depression | 1844 |
| Respiratory allergies | 95 |
| Respiratory depression | 244, 257 |
| Respiratory diseases | 613, 764 |
| Respiratory distress syndrome | 76 |
| Respiratory infections | 131, 140, 700 |
| Respiratory syncytial virus | 561,652 |
| Respiratory tract diseases | 2456 |
| Respiratory tract infections | 129, 132, 133, 134, 137, 140, 219, 341, 700 |
| Response to diuretics | 1051 |
| REST (RE1-silencing transcription factor) | 2174 |
| Resting heart rate | 1073 |
| Restless legs syndrome | 609, 665 |
| Restoration of water/sodium losses | 691 |
| Retinal artery occlusion | 2288 |
| Retinoblastoma | 190, 198, 906, 941, 1019, 2207, 2291, 2375 |
| Retinopathy | 2519 |
| Retinopathy of prematurity | 2300 |
| Retrolental fibroplasia | 750 |
| Retroviral transfer of human CYP450 genes | 1845 |
| REV-ERBalpha | 1929 |
| Reversal of nondepolarizing neuromuscular blockers | 632 |
| Reversible obstructive airway disease | 15, 31, 673 |
| Rhabdomyolysis | 906, 1376, 1471, 1561, 1845, 2147, 2415 |
| Rhabdomyosarcoma | 190, 196, 198, 791, 907, 2471 |
| Rhabdomyosarcoma and neuroblastoma | 907 |
| Rheumatic diseases | 613, 764 |
| Rheumatic fever | 53, 576 |
| Rheumatic heart disease | 2445, 2456 |
| Rheumatism | 255, 772 |
| Rheumatoid arthritis | 3, 5, 11, 42, 53, 60, 61, 116, 139, 141, 155, 192, 223, 284, 288, 291, 300, 321, 347, 348, 366, 383, 384, 408, 419, 440, 448, 459, 473, 506, 512, 550, 574, 597, 661, 708, 709, 724, 732, 738, 749, 764, 812, 907, 1062, 1155, 1191, 1201, 1228, 1237, 1327, 1918, 2058, 2139, 2140, 2145, 2198, 2200, 2211, 2216, 2278, 2290, 2295, 2337, 2347, 2408, 2439, 2456, 2465, 2471, 2515 |
| Rheumatoid disorders | 190, 371 |
| Rhinitis | 215, 368, 556 |
| Rhinorrhea | 393, 771 |
| Rho guanine nucleotide exchange factors PDZ-RhoGEF and LARG | 822 |
| Riboflavin deficiency | 653 |
| Ribosome inactivating protein | 2186 |
| Rickets | 110 |
| Rickettsia | 731 |
| Rigidity | 368 |
| Risk of coronary stent thrombosis | 610, 1420, 2226 |
| Risk of metabolic syndrome, diabetes or vascular disease | 2249 |
| Ritonavir-induced hyperlipidemia | 1929 |
| RNA interference | 908, 1156, 1850, 1972 |
| RNF2 (ring finger protein 2)(1q25.3) | 2174 |
| Rosacea | 61, 78, 248 |
| Rotavirus gastroenteritis | 668 |
| Roundworms | 453, 631 |
| Rubella | 379, 453, 669 |
| Runx2 | 1973 |
| S | |
| S100A12 | 1156 |
| Sacral chordoma | 909 |
| Salivary glands | 1853 |
| SALL4 | 1020 |
| Salmonella infection | 39 |
| Salmonellosis or shigellosis | 769 |
| Salt | 1620 |
| Salt sensitivity | 1395 |
| Salt-sensitive essential hypertension | 612, 1052 |
| Salt-sensitivity variants | 1853 |
| Salzmann nodular degeneration | 1020 |
| SANDO syndrome | 2335 |
| Sarcoidosis | 2145, 2157, 2519 |
| Sarcoma botryoides | 198 |
| S-Containing drugs and xenobiotics oxygenated by FMO1 | 2065 |
| Scabies | 188, 909 |
| Scalp seborrheic dermatitis | 672, 679 |
| Scavenger receptor class B type I (SR-BI) | 1156 |
| Scedosporium apiospermum | 795 |
| Scheie form of MPS I | 417 |
| Schistosoma mansoni infection, susceptibility/resistance to | 612 |
| Schistosomiasis | 612, 2216 |
| Schizoaffective disorder | 1064 |
| Schizophrenia | 49, 52, 95, 152, 178, 318, 319, 354, 374, 443, 474, 499, 541, 560, 582, 595, 620, 635, 658, 710, 735, 736, 766, 805, 810, 910, 1046, 1062, 1064, 1067, 1122, 1156, 1250, 1255, 1264, 1554, 1854, 1998, 2001, 2004, 2006, 2007, 2009, 2027, 2079, 2094, 2096, 2097, 2099, 2101, 2110, 2131, 2157, 2159, 2164, 2165, 2167, 2168, 2170, 2193, 2216, 2231, 2260, 2270, 2278, 2282, 2288, 2289, 2318, 2323, 2332, 2359, 2381, 2396, 2399, 2418, 2426, 2456, 2471, 2475, 2476 |
| Schizophrenia, susceptibility to | 1064, 1067, 1250, 1254, 1264, 1998, 2001, 2004, 2006, 2007, 2079, 2094, 2096, 2097, 2099, 2231, 2323 |
| Schizophrenia-related weight gain | 1064 |
| Sciatica | 702 |
| Scleroderma | 607 |
| Sclerosing cholangitis | 910 |
| Scorpion alcoholic extraction | 910 |
| Scott syndrome | 822 |
| Scurvy | 51 |
| Seasonal affective disorder | 702, 2164 |
| Seasonal allergic conjunctivitis | 409, 410, 424, 441, 457, 516, 543, 613 |
| Seasonal allergic rhinitis | 69, 97, 121, 142, 151, 157, 168, 187, 193, 438, 500, 584, 764, 771 |
| Seasonal changes | 1291, 1973 |
| Seborrheic dermatitis | 78, 158, 179, 672 |
| Second- and third-degree burns | 445, 685 |
| Secondary amenorrhea | 456, 621 |
| Secondary hyperparathyroidism | 109, 161, 566 |
| Secondary Parkinson’s disease | 609 |
| Secondary pulmonary hypertension | 612, 684, 689 |
| Sedation | 145, 301, 624 |
| Sedative/hypnotic withdrawal | 577 |
| Seizure disorders | 174, 669, 781 |
| Seizures | 278, 334, 584, 669, 781, 1535 |
| Seizures and myoclonus | 1483, 1535 |
| Selenium and vitamin E deficiency | 1904 |
| Senile chorea | 729 |
| Senile cognitive impairment | 166 |
| Senile dementia | 272, 360, 620, 662, 750 |
| Senile dementia of Alzheimer’s type | 141, 166, 620, 662, 713 |
| Sepsis | 138, 251, 1291, 2050, 2216, 2256 |
| Sepsis-induced drug metabolizing dysfunction | 1608 |
| Septic arthritis | 309 |
| Septic shock | 214, 785, 2456 |
| Septicemia | 129, 132, 133, 137, 309, 310, 341, 549, 740 |
| Serotonergic 5-HT2A receptor signaling | 1973 |
| Serotonergic 5HTR6 compounds inducing hypophagia | 2170 |
| Serotonin syndrome | 1536, 1555 |
| Serotonin transporter | 1556 |
| Serratia | 29 |
| Serum incubation method | 1856 |
| Serum lipid levels and metabolic syndrome | 2150 |
| Serum opacity factor | 995 |
| Serum thyroglobulin testing | 737 |
| Severe acne | 169 |
| Severe acute respiratory syndrome | 1034 |
| Severe burns | 685 |
| Severe combined immune deficiency | 2242 |
| Severe combined immunodeficiency due to ADA deficiency | 1049 |
| Severe combined immunodeficiency syndromes | 380 |
| Severe congenital protein C deficiency | 628 |
| Severe congestive heart failure | 241 |
| Severe fibrosis | 1985 |
| Severe heart failure | 701 |
| Severe malaria anemia | 2216 |
| Severe myoclonic epilepsy | 2386 |
| Severe pain | 409, 427, 555, 717, 758, 803 |
| Severe primary axillary hyperhidrosis | 90 |
| Severely-restricted mobility | 263 |
| Sevoflurane, Isoflurane, Propofol or Dexmedetomidine anesthesia | 959, 1930 |
| Sex determination and disorders of sex development | 1973 |
| Sex steroids | 1857, 1973 |
| Sex-related differences | 1523, 1856 |
| Sex-related metabolic profiles | 1559 |
| Sexual development | 1973 |
| Sexual dysfunction | 1536 |
| Sexually-transmitted disease | 63 |
| Sézary syndrome | 1993 |
| Shigellosis | 39, 131 |
| Shock | 15, 218, 241, 265, 535, 2157 |
| Short bowel syndrome | 456 |
| Short QT syndrome | 2236 |
| Short QT syndrome 1 | 2232 |
| Short QT syndrome 2 | 2236 |
| Short stature | 697, 2088 |
| Short-term treatment of insomnia | 677, 720, 765, 802, 809 |
| Shoulder-hand syndrome | 724 |
| Sialorrhea | 90, 368 |
| Sick building syndrome | 1608 |
| Sick sinus syndrome | 2390 |
| Sickle cell anemia | 2125 |
| Sickle-cell disease | 367, 1420 |
| Side chain-oxidized oxysterols | 1985 |
| Sigma receptors | 910, 1156 |
| Silent myocardial ischemia | 1067 |
| Silver-Russell syndrome | 2190 |
| Single ventricle | 1941 |
| Sinus bradycardia | 59 |
| Sinus congestion | 771 |
| Sinus tachycardia | 279 |
| Sinusitis | 38, 512, 556, 630 |
| SIRT1 | 822 |
| Situational anxiety | 620 |
| Sjögren’s syndrome | 143 |
| Skeletal metastases | 704 |
| Skeletal muscle pain | 123, 772 |
| Skeletal muscle relaxant | 646, 747 |
| Skeletal myopathy, responsive to riboflavin | 2285 |
| Skin | 1861 |
| Skin and skin structure infections | 129, 130, 131, 132, 133, 134, 135, 137, 140, 168, 430, 465, 483, 503, 540, 740, 741 |
| Skin and soft tissue infections | 138, 341,700 |
| Skin cancer | 1096, 2031, 2216, 2471 |
| Skin cleanser | 148 |
| Skin discoloration | 365 |
| Skin disorders | 2154 |
| Skin infections | 128, 129, 130, 131, 132, 133, 134, 135, 137, 140, 168, 341, 426, 430, 465, 483, 503, 519, 540, 639, 700, 707, 740, 741 |
| Skin lesions | 26 |
| Skin resurfacing | 764 |
| Sleep disorders | 497 |
| Sleep initiation and maintenance disorders | 791, 808 |
| Small-cell lung cancer | 290, 755, 911, 941, 964, 1020, 1989, 2102, 2103, 2528 |
| Small heterodimer partner (SHP) | 1930 |
| Small interfering RNA (siRNA) | 911 |
| Smallpox | 690, 2288 |
| Smallpox vaccine | 690, 2288 |
| Smith-Lemli-Opitz syndrome | 823 |
| Smokeless tobacco | 1328 |
| Smoking | 524, 784, 823, 1291, 1328, 1354, 1366, 1470, 1488, 1524, 1531, 1620, 1862, 2260 |
| Sneezing | 771 |
| S-Nitrosylation | 1157 |
| Social anxiety disorder | 324, 567 ,681, 787, 1061 |
| Social phobia | 787 |
| Sodium depletion | 1941 |
| Soft tissue infections | 700 |
| Soft tissue or skeletal infections | 131 |
| Soft tissue sarcoma | 88, 196, 198, 247, 791, 1189 |
| Solar keratosis | 316 |
| Solid tumor malignancies | 647, 712 |
| Solid-organ transplantation | 1862 |
| Solute carriers | 1863 |
| Soman nerve gas exposure | 632 |
| Somatic colon cancer | 2344 |
| Somatic gastric cancer | 2224 |
| Somatic gastrointestinal stromal tumor | 2329 |
| Somatic mutations in pituitary adenomas | 2091 |
| Somatic pilocytic astrocytoma | 2241 |
| Somatoform disorders | 702 |
| Sonic hedgehog | 1941 |
| Sore throat pain | 585 |
| Sorsby fundus dystrophy | 2450 |
| Sour stomach | 160, 296 |
| Spasm | 677 |
| Spastic colon | 768 |
| Spasticity | 200, 790 |
| Species differences | 1329, 1366, 1396, 1608, 1620 |
| Species differences and evolutionary origins | 1973 |
| Sperm | 1292 |
| Spermatogenesis | 156, 325, 326, 1975 |
| Sperm whale skin biopsies | 1292 |
| Sphingomyelins | 995, 1157, 1178, 1183 |
| Sphingosine kinase | 941 |
| Sphingosine 1-phosphate | 2212, 2237 |
| Sphingosine-1-phosphate receptors | 1157 |
| Spina bifida | 2297, 2337 |
| Spina bifida and neural tube defect | 2405 |
| Spinal and bulbar muscular atrophy | 1186 |
| Spinal anesthesia | 619, 706, 730 |
| Spinal cord injury | 65, 200, 984 |
| Spondylolisthesis | 271 |
| Spontaneous abortion | 1930, 2136 |
| Spontaneous preterm birth | 2361 |
| Sporadic amyotrophic lateral sclerosis | 656, 1111, 2104, 2528 |
| Sporadic breast cancer | 1196 |
| Sporadic colorectal adenocarcinomas | 1046 |
| Sporadic solitary aldosterone- and cortisol-co-secreting adenomas | 1942 |
| SPRED2 (sprouty-related protein with EVH1 domain 2) | 1942 |
| Squamous cell carcinoma | 88, 913 |
| Squamous cell carcinoma of the head and neck | 143, 237, 367, 2505 |
| Squamous cell carcinoma of the larynx and hypopharynx | 1608, 1623, 1590, 1864 |
| Squamous cell lung carcinoma | 1292 |
| SSRI-induced sexual dysfunction | 800 |
| SSRI-related hyponatremia | 1479, 1536 |
| SSRIs, TCAs and neuroleptics | 1479 |
| Stable angina | 788 |
| Stable monomorphic VT | 618 |
| Staining of anterior capsule of the lens | 774 |
| Staphylococcal infections | 39, 309, 337, 508, 639, 654, 741, 783 |
| Staphylococcus aureus bacteremia | 201, 504, 639, 741 |
| STAT3 decoy oligodeoxynucleotides | 913 |
| Static magnetic field | 913 |
| Stature quantitative trait locus | 1237 |
| Status asthmaticus | 673 |
| Status epilepticus | 439, 781 |
| Stearoyl-Coenzyme A | 2106 |
| Steatohepatitis | 78 |
| Steatosis | 2292 |
| Stem cells | 941, 1366, 1609, 1930 |
| Stent thrombosis | 610, 914, 1396 |
| Steroid receptor coactivator 2 (SRC-2) | 1975 |
| Steroid-induced osteonecrosis | 914 |
| Steroidogenic acute regulatory protein | 996 |
| Steroidogenic factor-1 (SF-1) | 1942 |
| Steroid-resistant asthma | 914 |
| Sterol carrier protein-2 | 1930 |
| Stevens-Johnson syndrome | 2131, 2134 |
| Stimulation of pancreatic secretion for analysis | 687 |
| Stomach | 1869 |
| Stomach cancer | 316, 494 |
| Stomatitis | 73, 119, 255 |
| Strabismus | 90 |
| Strategies for minimizing mechanism-based inhibition of CYP3A4 | 1869 |
| Streptococcal or enterococcal endocarditis | 39, 309, 549, 704 |
| Streptococcal serum opacity factor | 1157 |
| Streptococcus pneumoniae | 63, 134 |
| Streptozotocin-induced diabetic nephropathy | 1621 |
| Stress | 343, 2306 |
| Stress/anxiety | 144, 620, 702 |
| Stress-related diseases | 2062 |
| Stroke | 53, 176, 200, 523, 611, 643, 740, 823, 941, 1034, 1079, 1118, 1228, 1270, 1421, 1869, 1907, 1910, 1942, 2038, 2048, 2050, 2198, 2300, 2337 |
| Stroke, susceptibility to | 1079, 1270, 2337 |
| Stroke-like-episodes | 2284 |
| Strongyloidiasis | 403, 733 |
| Structure-activity relationship analysis of CYP450 metabolism | 1870 |
| ST-segment elevation myocardial infarction | 263, 651, 722, 739 |
| Sturge-Weber syndrome with congenital glaucoma | 1345 |
| Subacute sclerosing panencephalitis | 2203 |
| Subacute stent thrombosis | 610, 740 |
| Subarachnoid hemorrhage | 528, 759, 1158 |
| Substance abuse | 2007, 2162, 2164 |
| Substrate preferences | 1870 |
| Substrate-dependent activity of CYP2D6 isoenzymes | 1562 |
| Sucrase deficiency | 671 |
| Sudden cardiac arrest | 1034 |
| Sudden cardiac death | 2390 |
| Sudden death | 2236 |
| Sudden infant death syndrome | 2159, 2198, 2216, 2282, 2285 |
| Sudden sensorineural hearing loss | 1292 |
| Suicidal behavior | 2396 |
| Suicidal ideation | 914 |
| Suicide | 2165 |
| Sulfonylurea-induced hypoglycemia | 1396 |
| Sulfonylurea receptor 2A | 985 |
| Sulfonylurea receptor 2B | 985 |
| Sulfotransferases | 1870 |
| Sunburn | 73 |
| Superficial eye infections | 602, 748, 768 |
| Superficial mycoses | 177 |
| Suppression of Rh isoimmunization | 651 |
| Suprapubic pain | 307 |
| Supraventricular tachyarrhythmias | 227, 229, 279, 308, 623, 626, 788 |
| Susceptibility to arsenic-induced diseases | 1190, 1220 |
| Susceptibility to atypical hemolytic uremic syndrome | 2449 |
| Susceptibility to carcinogens | 2120 |
| Susceptibility to cleft lip/palate | 2291 |
| Susceptibility to diabetic nephropathy | 2129 |
| Susceptibility to different types of cancer | 2031 |
| Susceptibility to essential hypertension | 612, 1063, 1066, 1068, 1071, 1077, 1081, 1197, 2093 |
| Susceptibility to hip fracture | 2227 |
| Susceptibility to obsessive-compulsive disorder | 2096 |
| Susceptibility to recurrent viral infections | 2059 |
| Susceptibility to UV-induced sun damage | 2267 |
| Susceptibility to West Nile virus | 1228 |
| Sweetening agent | 698 |
| Sympathetic ophthalmia | 764 |
| Sympathoadrenal, metabolic, and hormonal balance | 2306 |
| Symptomatic parkinsonism | 120 |
| Syndrome of inappropriate ADH secretion (SIADH) | 754 |
| Synovitis | 764 |
| Syphilis | 248, 255, 276, 731 |
| Systemic carnitine deficiency | 425 |
| Systemic fungal infections | 407 |
| Systemic juvenile rheumatoid arthritis | 2207 |
| Systemic lupus erythematosus | 764, 1201, 1421, 1609, 1975, 1985, 2038, 2056, 2059, 2110, 2145, 2157, 2203, 2208, 2216, 2295, 2439, 2456, 2466 |
| Systemic mastocytosis | 187 |
| Systemic sclerosis | 1201, 1562, 2139, 2300, 2439 |
| Systolic blood pressure in preterm infants | 1562 |
| Systolic hypertension | 153, 612 |
| T | |
| Tachycardia | 355, 1073 |
| Tachypnea | 301 |
| Tamoxifen resistance | 2026 |
| Tangier disease | 823 |
| Tardive dyskinesia | 710, 729, 750, 790, 1258, 1330, 1566, 1875, 2002, 2004, 2422 |
| Tauopathies | 1158, 2264 |
| Tau-tubulin kinase-1 | 1158 |
| T-cell acute lymphoblastic leukemia | 517, 966 |
| T-cell leukemia | 608 |
| T-cell lymphoblastic lymphoma | 517, 608, 1875 |
| T-cell prolymphocytic leukemia, sporadic | 608 |
| TGFβ1 | 1931 |
| Telangiectasia | 2471 |
| Telomere shortening | 1976 |
| Temporal arteritis | 764 |
| Temporomandibular joint pain | 123 |
| Tenascin-C | 917 |
| Tendinitis | 383, 709, 724 |
| Test to evaluate thyroid function | 628, 692 |
| Testicular cancer | 88, 146, 164, 190, 198, 290, 374, 791, 2272 |
| Testicular germ cell cancer | 1329, 1877, 2335 |
| Testicular steroids | 1354, 1609 |
| Testicular tumors | 198, 290, 790 |
| Testotoxicosis | 1961 |
| Tetanus | 152, 379, 472, 729 |
| Tetrahydrobiopterin (BH4) responsive phenylketonuria | 674 |
| Tetrahydrobiopterin-deficient hyperphenylalaninemia due to GTP cyclohydrolase I deficiency | 2082 |
| Thalassemia | 206, 1330, 1878 |
| Thalidomide-related neuropathy | 823 |
| Therapeutic abortion | 1965 |
| Therapy-related acute myeloid leukemia (t-ML) | 2274, 2308 |
| Thiamine deficiency | 733 |
| Third degree burns | 685 |
| Thrombocytopenia | 41, 260, 420, 546, 665, 2200, 2227 |
| Thrombocytopenic purpura | 380, 2227 |
| Thromboembolic disease | 6, 233, 420, 797 |
| Thromboembolic stroke | 611, 2203 |
| Thromboembolism | 356, 797, 2050, 2353 |
| Thrombophilia | 2449 |
| Thrombophilia due to activated protein C resistance | 2050 |
| Thrombophilia due to factor V Leiden | 2050 |
| Thromboprophylaxis | 196 |
| Thrombosis | 48, 199, 1158, 2227, 2288 |
| Thrombotic stroke | 233, 611, 740 |
| Thymine | 1995 |
| Thymocytes | 919 |
| Thymocyte and lymphocyte proliferation | 996 |
| Thyroid cancer | 247, 692, 737, 1021, 2018, 2026, 2297, 2450, 2489, 2511 |
| Thyroid disease | 919, 1992, 2434 |
| Thyroid dysfunction | 2230 |
| Thyroid dyshormogenesis | 2392 |
| Thyroid function | 628, 692 |
| Thyroid hormone | 1991, 2417 |
| Thyroid nodules | 737 |
| Thyroid papillary carcinoma | 2270 |
| Thyroidectomy | 737 |
| Thyroiditis | 737 |
| Thyrotoxic crisis | 627 |
| Thyrotoxicosis | 737 |
| Ticlopidine-induced hepatotoxicity | 2131 |
| Tie1 | 1158 |
| Time-dependent CYP450 inhibition | 1880 |
| Tinea corporis | 104, 158 |
| Tinea cruris | 104, 158 |
| Tinea pedis | 104, 158 |
| TNFα | 1610, 1931 |
| Tinnitus | 161, 342, 2399 |
| TMCC2 | 1158 |
| Tobacco | 1292, 1610 |
| Tobacco smoking | 1067 |
| Tobacco use disorder | 1253, 1255, 1610, 1989, 2006, 2259 |
| Tobacco-related cancers | 2505 |
| Tocopherol-ω-hydroxylase | 1910 |
| Toll-like receptor 2 (TLR2) | 1159 |
| Toll-like receptor 4 (TLR4) | 1159 |
| TOMM40 poly-T variants | 1159 |
| Tonic-clonic (grand mal) seizures | 287, 617 |
| Tonsillar disease | 2453 |
| Tonsillitis | 255 |
| Tooth agenesis | 1249 |
| Toothache | 234 |
| Topical infections | 608 |
| Topoisomerase I | 1022 |
| Torg-Winchester syndrome | 2276 |
| Torsades de pointes | 449, 1882, 2232 |
| Torsades de pointes, drug-associated | 2232 |
| Torulopsis glabrata | 39 |
| Tourette’s syndrome | 354, 591, 729, 805, 2002, 2198 |
| Toxoplasma gondii | 633, 708, 768 |
| Toxoplasma gondii encephalitis | 58, 2141 |
| Toxoplasma gondii infection | 633, 708, 768 |
| Toxoplasmosis | 633, 708, 768 |
| Trace metal deficiencies | 757 |
| Trachoma | 707, 2153, 2216 |
| TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) | 919 |
| TRAIL death receptor 5 (DR5) | 919 |
| Transcription factor | 2071 |
| Transcriptional activation of CYP3A4 | 2150 |
| Transcriptome | 1159 |
| Transforming growth factor beta (TGFB) | 1610 |
| Transforming growth factor-beta1 (TGFB1) | 996, 1610 |
| Transient ischemic attacks | 6, 233, 523, 797 |
| Transient neonatal diabetes mellitus | 985, 2234 |
| Transitional cell carcinoma | 793 |
| Transkingdom RNAi | 920 |
| Transplant recipients | 1883 |
| Transplant-associated coronary disease | 2177 |
| Transplant-free survival for single ventricle patients | 2012 |
| Transporter-enzyme interactions | 1883 |
| Transurethral prostatic resection | 698 |
| Traumatic brain injury | 342, 1159 |
| Traumatic spinal cord injury | 1159 |
| Travelers’ diarrhea | 655, 761, 769 |
| Treatment of acute lymphocytic leukemia | 723, 792 |
| Treatment of growth failure associated with chronic renal insufficiency | 697 |
| Treatment of short stature or growth failure associated with short stature homeobox gene deficiency | 697 |
| Treatment of short-bowel syndrome | 697 |
| Treatment of tinea versicolor and acne | 553, 679, 695, 707, 725 |
| Treatment-resistant depression | 774 |
| Trefoil factor 1 (TTF1) | 1976 |
| Tremor | 368, 1376 |
| Treponema pallidum | 575 |
| Trichinosis | 613, 733 |
| Trichomoniasis | 743 |
| Tricuspid atresia | 24 |
| Trifluoromethylpyrimidine class of tyrosine kinase 2 (PYK2) inhibitors | 1885 |
| Trigeminal neuralgia | 748 |
| Trigeminal/glossopharyngeal/diabetic neuralgia | 118 |
| Triglycerides | 2196, 2210, 2301, 2318, 2338, 2463 |
| Triiodothyronine | 1046, 1054, 1183, 1223, 1262, 1613, 1885, 1992, 2054, 2074, 2075, 2082, 2086, 2118, 2125, 2159, 2253, 2275, 2276, 2318, 2333, 2376, 2447, 2463 |
| Trilostane (3β-hydroxysteroid dehydrogenase inhibitor) | 1977 |
| Trimethylaminuria | 2068 |
| Trophoblastic neoplasms | 473 |
| Tuberculosis | 32, 68, 116, 285, 286, 397, 613, 631, 654, 704, 920, 1887, 2067, 2183, 2220, 2402, 2407, 2466, 2515 |
| Tularemia | 704 |
| Tumor necrosis factor-alpha (TNF) | 920, 996, 1022, 1145 |
| Tumor proliferation | 1621 |
| Tumorigenesis | 2072 |
| Tumor-induced angiogenesis | 2276 |
| Turner’s syndrome | 697 |
| Type 1 Gaucher’s disease | 786 |
| Type III hyperlipoproteinemia | 1159 |
| Type III hyperlipoproteinemia associated with APOE deficiency | 1160 |
| Type III hyperlipoproteinemia due to APOE4-Philadelphia | 1160 |
| Typhoid fever | 162, 255, 769, 2145 |
| Tyroid carcinoma | 2515 |
| U | |
| Ubiquitin-dependent proteasomal degradation | 1610 |
| UDP-glucuronosyltransferase 2B7 modulation | 1887 |
| UGT1A9 regulation by BRCA1 | 2502 |
| UHRF1 | 921 |
| Ulcerative colitis | 66, 363, 384, 466, 543, 699, 708, 921, 970, 1258, 1355, 2116, 2120, 2150, 2200, 2217, 2312, 2344, 2456, 2528 |
| Ulcerative gastroesophageal reflux disease | 415, 640 |
| Ultra-rapid metabolizers | 1507 |
| Ultrasound | 921 |
| Ultraviolet-induced dyschromia | 365 |
| Unresponsive hyperinsulinemic hypoglycemia | 985 |
| Unstable angina | 87, 176, 199, 263, 327, 610, 738, 739, 788 |
| Upper airway secretions | 347 |
| Upper and lower respiratory tract infections | 138, 255, 700 |
| Upper gastrointestinal tract cancer | 1096 |
| Upper GI bleeding | 240 |
| Upper respiratory allergies | 630 |
| Urate/uric acid and gout | 617, 1022 |
| Urea cycle disorder | 693 |
| Ureteral spasm | 624 |
| Urethra gonorrhea | 700, 731 |
| Urethritis | 63, 307, 540 |
| Urethrocystitis | 307 |
| Urethrotrigonitis | 307 |
| Uric acid | 647 |
| Urinary bladder neoplasms | 2480 |
| Urinary bladder spasm | 624 |
| Urinary burning | 255 |
| Urinary incontinence | 265, 304, 1977 |
| Urinary outflow obstruction | 244, 306 |
| Urinary retention | 306 |
| Urinary tract infection | 8, 119, 128, 129, 131, 132, 133, 134, 137, 138, 162, 191, 242, 255, 275, 310, 330, 377, 471, 509, 532, 536, 583, 708, 709, 740, 768, 769, 1905, 2453 |
| Urine alkalinization | 604, 606 |
| Urokinase plasminogen activator | 1160 |
| Urolithiasis | 2516 |
| Urothelial carcinoma | 793, 1611, 2112, 2113 |
| Urticaria | 121, 142, 151, 168, 193, 215, 773 |
| Uterine atony | 273 |
| Uterine leiomyoma | 422, 1345, 2528 |
| Uterine sarcomas | 198 |
| Uveal melanoma | 1241 |
| Uveal tract inflammation | 359 |
| Uveitis | 59, 314, 316, 764 |
| V | |
| Vaginal irritation | 608 |
| Vancomycin-resistant Enterococcus faecium infections | 430, 639 |
| Vancomycin-sensitive Enterococcus faecalis | 741 |
| Varicella | 379,453 |
| Varicella zoster | 10 |
| Varicella zoster virus in pregnant women | 785 |
| Varicocele-associated male infertility | 1977 |
| Varicose veins | 502, 695 |
| Varicosis | 1621 |
| Vascular calcification | 1160 |
| Vascular dementia | 342, 523, 1160, 2456 |
| Vascular disorders | 523, 2300 |
| Vascular factors | 1160 |
| Vascular failure | 587 |
| Vascular headaches | 273, 479 |
| Vascular injury | 1160 |
| Vasoactive intestinal peptide, 4-chloro-Phe6-Leu17- | 2447, 2520 |
| Vasodilatory shock | 785 |
| Vasomotor rhinitis | 62, 95, 121 |
| Vasospastic (Prinzmetal’s) angina | 34,788 |
| Vein graft disease | 1160 |
| Venoocclusive disease | 1889 |
| Venous thromboembolism | 199, 628, 797, 1398, 2203, 2325 |
| Venous thrombosis | 6, 218, 356, 797, 2050, 2364 |
| Ventricular arrhythmias/tachycardia | 5, 398, 429, 485, 501, 698, 699 |
| Ventricular asystole | 59 |
| Ventricular fibrillation | 32, 785 |
| Ventricular premature complexes | 235 |
| Ventricular tachycardia | 32, 308, 501, 618, 626, 785, 1073, 2390 |
| Vernal conjunctivitis | 187, 435, 457 |
| Vernal keratitis | 187, 435 |
| Vernal keratoconjunctivitis | 187, 435 |
| Vertebral fractures | 1977 |
| Vertigo | 161, 189, 230, 342, 454, 710, 791 |
| Vestibular disorders | 161 |
| Vestibular vertigo | 313, 791 |
| Vincent’s infection | 119 |
| Viral croup | 266 |
| Viral infection | 2180 |
| Visceral pain syndromes | 234, 287 |
| Visual disorders | 342 |
| Vitamin A deficiency | 651 |
| Vitamin B6 deficiency | 632 |
| Vitamin B12 deficiency | 188, 366 |
| Vitamin C deficiency | 1611 |
| Vitamin D deficiency | 154 |
| Vitamin D3 hydroxylase | 1986 |
| Vitamin D3 25-hydroxylases | 1621 |
| Vitamin D-dependent rickets (type II) | 2516 |
| Vitamin deficiencies | 795 |
| Vitamin E deficiency | 750 |
| Vitamin K1 oxidase | 1911 |
| Vitiligo | 474, 500, 1215 |
| Vitreal kinetics | 924 |
| Vomiting | 161, 230,239 |
| von Hippel-Lindau disease | 1221 |
| von Willebrand disease | 44, 211 |
| Vulvar and vaginal atrophy | 281, 283 |
| Vulvitis | 798 |
| Vulvovaginal candidiasis | 104, 177, 310, 486, 681, 725, 744 |
| W | |
| Waldenström’s macroglobulinemia | 732 |
| Warts | 115, 672, 766 |
| Water channel | 1895 |
| WAVE1 | 924 |
| Wegener’s granulomatosis | 190 |
| Weight gain | 1064, 1524, 1549 |
| Weight loss | 78, 800, 1046, 1082 |
| Wernicke’s encephalopathy | 733 |
| Whipworms | 453 |
| White matter changes | 1161 |
| Whole blood serotonin | 2227 |
| Wilms’ tumor | 198, 247, 791, 925 |
| Wilson’s disease | 574, 766, 2198 |
| Wiskott-Aldrich syndrome | 380 |
| Wolff-Parkinson-White syndrome | 623 |
| Wound cleansing, irrigation, and flushing | 691 |
| Wound irrigation | 691, 692 |
| Wounds and injuries | 449, 701, 805 |
| X | |
| Xanthelasma | 675 |
| Xanthinuria | 2525 |
| Xenobiotics | 925, 961, 1096, 1471, 2105, 2314 |
| Xenobiotic and endobiotic metabolism | 1905 |
| Xeroderma pigmentosum | 2032 |
| Xeroderma pigmentosum, complementation group A | 2526 |
| Xerostomia | 590, 672 |
| X-linked adrenoleukodystrophy | 1911 |
| X-linked cutis laxa | 1193 |
| X-linked immunodeficiency | 380 |
| X-linked mental retardation | 2094 |
| X-linked mental retardation type 94 (MRX94) | 2094 |
| Z | |
| Zinc and Paraquat co-exposure | 1611 |
| Zinc supplement | 805 |
| ZFAND6 function | 2529 |
| Zollinger-Ellison syndrome | 279, 296, 415, 564, 640 |
